

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: William J. McBRIDE et al.

Title: RADIOMETAL-BINDING  
PEPTIDE ANALOGUES

Prior Appl. No.: 08/893,749

Prior Appl. Filing Date: 7/11/1997

Examiner: Unassigned

Art Unit: Unassigned

**DIVISIONAL PATENT APPLICATION**  
**TRANSMITTAL LETTER**

Commissioner for Patents  
Box PATENT APPLICATION  
Washington, D.C. 20231

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is a:

☐ Divisional ☒ Division ☐ Divisional-In-Part (CIP)

of the above-identified co-pending prior application in which no patenting, abandonment, or termination of proceedings has occurred. Priority to the above-identified prior application is hereby claimed under 35 U.S.C. § 120 for this continuing application. The entire disclosure of the above-identified prior application is considered as being part of the disclosure of the accompanying continuing application and is hereby incorporated by reference therein.

Enclosed are:

- ☒ Specification, Claim(s), and Abstract (55 pages).
- ☒ Copy of Declaration and Power of Attorney (2 pages).
- ☒ Small Entity statement.
- ☒ Preliminary Amendment
- ☒ Information Disclosure Statement.
- ☒ Form PTO-1449 (2 pgs.)

The filing fee is calculated below:

	Claims as Filed	Included in Basic Fee	Extra Claims	Rate	Fee Totals
Basic Fee				\$710.00	\$710.00
Total Claims:	21	- 20	= 1	x \$18.00	= \$18.00
Independents:	1	- 3	= 0	x \$80.00	= \$0.00
If any Multiple Dependent Claim(s) present:			+	\$270.00	= \$0.00
				SUBTOTAL:	= \$728.00
[ X ]				Small Entity Fees Apply (subtract ½ of above):	= \$364.00
				TOTAL FILING FEE:	= \$364.00

- [ X ] A check in the amount of \$364.00 to cover the filing fee is enclosed.
- [ ] The required filing fees are not enclosed but will be submitted in response to the Notice to File Missing Parts of Application.
- [ X ] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date October 2, 2000

By Patricia A. Navados #33,663

FOLEY & LARDNER  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5109  
Telephone: (202) 672-5427  
Facsimile: (202) 672-5399

Bernhard D. Saxe  
Attorney for Applicant  
Registration No. 28,665

Applicant or Patentee: William I. McBride et al

Serial or Patent No.: 08/893,749 Atty. Dkt. No. 018733/0804

Filed or Issued: July 11, 1997

For: RADIOMETAL-BINDING PEPTIDE ANALOGUES

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS  
(37 CFR 1.9(f) AND 1.27 (c)) — SMALL BUSINESS CONCERN**

I hereby declare that I am

☐ the owner of the small business concern identified below:

☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN Immunomedics, Inc.

ADDRESS OF CONCERN 300 American Road, Morris Plains, New Jersey 07950

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18 and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled RADIOMETAL-BINDING PEPTIDE ANALOGUES by inventor(s) described in

☐ the specification filed herewith

☒ application serial no. 08/893,749, filed July 11, 1997

☐ patent no. \_\_\_\_\_, issued \_\_\_\_\_

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e). \* NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities: (37 CFR 1.27)

NAME: \_\_\_\_\_

ADDRESS: \_\_\_\_\_

☐ INDIVIDUAL

☐ SMALL BUSINESS CONCERN

☐ NONPROFIT CORPORATION

NAME: \_\_\_\_\_

ADDRESS: \_\_\_\_\_

☐ INDIVIDUAL

☐ SMALL BUSINESS CONCERN

☐ NONPROFIT CORPORATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate: (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: David M. Goldenberg, Sc.D., M.D.

TITLE OF PERSON OTHER THAN OWNER: Chairman and Chief Executive Officer

ADDRESS OF PERSON SIGNING: 300 American Road, Morris Plains, New Jersey 07950

SIGNATURE: 

DATE: Sept. 9, 1997

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Attorney Docket No: 018733/0997**

*In re* patent application of  
William J. McBRIDE *et al.*

Serial No.: Divisional of  
U.S. Serial No. 08/839,749

Group Art Unit: Unassigned

Filed: Concurrently

Examiner: Unassigned

For: RADIOMETAL-BINDING PEPTIDE ANALOGUES

**Preliminary Amendment**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:


Before action is taken by the Examiner, please amend the captioned application as follows:

**In the Claims:**

Please cancel claims 1-23 and add the following new claims.

24. A method of treating a tumor, an infectious lesion, a myocardial infarction, a clot, atherosclerotic plaque, or a normal organ or tissue, comprising administering to a human patient a radiolabeled peptide, together with a pharmaceutically acceptable carrier,

wherein said radiolabeled peptide is prepared by contacting a solution of a peptide with stannous ions, wherein said peptide comprises a radiometal-binding moiety comprising the structure:



wherein  $R^1$ ,  $R^2$ , and  $R^3$  independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, and a protecting group that can be removed under the conditions of peptide synthesis, provided that at least one of  $R^1$ ,  $R^2$ , or  $R^3$  is H,

$R^5$ ,  $R^7$ ,  $R^8$ ,  $R^9$  and  $R^{10}$  independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, aryl, and substituted aryl, and  $R^8$  and  $R^9$  together or  $R^7$  and  $R^9$  together may form a cycloalkyl or substituted cycloalkyl ring,

$R^4$  and  $R^6$  together form a direct bond or are independently selected from the group consisting of lower alkyl, substituted lower alkyl, aryl, and substituted aryl, and wherein  $NR^{10}$  is located at the N-terminus of said peptide, or is located on an amino acid side chain of said peptide,

and then contacting said solution with a radionuclide and recovering the radiolabeled peptide.

25. A method according to claim 24, wherein  $R^1$  is H.
26. A method according to claim 24, wherein  $R^3$  is H.
27. A method according to claim 24, wherein  $R^4$  is H.
28. A method according to claim 24, wherein  $R^4$  and  $R^6$  together form a direct bond.
29. A method according to claim 24, wherein  $R^5$  is H.

30. A method according to claim 24, wherein NR<sup>10</sup> is located at the N-terminus of said peptide.

31. A method according to claim 24, wherein NR<sup>10</sup> is located on an amino acid side chain of said peptide.

32. A method according to claim 25, wherein R<sup>2</sup> is lower alkyl or substituted or unsubstituted phenyl.

33. A method according to claim 32, wherein R<sup>2</sup> is H.

34. A method according to claim 33, wherein R<sup>3</sup> is H.

35. A method according to claim 34, wherein R<sup>4</sup> and R<sup>6</sup> together form a direct bond.

36. A method according to claim 34, wherein R<sup>5</sup> is H.

37. A method according to claim 36, wherein R<sup>7</sup>, R<sup>8</sup>, and R<sup>9</sup> each are H.

38. A method according to claim 37, wherein R<sup>2</sup> is phenyl.

39. A method according to claim 37, wherein R<sup>2</sup> is methyl.

40. A method according to claim 24, wherein R<sup>8</sup> and R<sup>9</sup> are methyl.

41. A method according to claim 24, wherein said peptide is selected from the group consisting of:

(Chel) $\gamma$ AbuNleDHF<sub>4</sub>RWK-NH<sub>2</sub>,

(Chel) $\gamma$ AbuHSDAVFTDNYTRLRKQMAVKKYLNSILN-NH<sub>2</sub>,

KPRRPYTDNYTRLRK(Chel)QMAVKKYLNSILN-NH<sub>2</sub>,

(Chel) $\gamma$ AbuVFTDNYTRLRKQMAVKKYLNSILN-NH<sub>2</sub>,

(Chel) $\gamma$ AbuYTRLRKQMAVKKYLSILN-NH<sub>2</sub>,  
 HSDAVFTDNYTRLRK(Chel)QMAVKKYLSILN-NH<sub>2</sub>, < GHWSYK(Chel)LRPG-NH<sub>2</sub>,  
 < GHYSLK(Chel)WKPG-NH<sub>2</sub>, AcNaI<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub>(Chel)LRPA<sub>d</sub>-NH<sub>2</sub> ,  
 (Chel) $\gamma$ AbuSYSNleDHF<sub>d</sub>RWK-NH<sub>2</sub>, (Chel) $\gamma$ AbuNleDHF<sub>d</sub>RWK-NH<sub>2</sub> ,  
 (Chel)NleDHF<sub>d</sub>RWK-NH<sub>2</sub> ,  
 Ac-HSDAVFTENYTKLRK(Chel)QNleAAKKYLNDLKKGGT-NH<sub>2</sub>,  
 (Chel) $\gamma$ AbuHSDAVFTDNYTRLRKQMAVKKYLSILN-NH<sub>2</sub>,  
 (Chel) $\gamma$ AbuVFTDNYTRLRKQMAVKKYLSILN-NH<sub>2</sub>, (Chel) $\gamma$ AbuNleDHF<sub>d</sub>RWK-NH<sub>2</sub><sup>c</sup>,  
 < GHWSYK(Chel)LRPG-NH<sub>2</sub>, < GHYSLK(Chel)WKPG-NH<sub>2</sub>,  
 AcNaI<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub>(Chel)LRPA<sub>d</sub>-NH<sub>2</sub>, < GHYSYLK(Chel)WKPG-NH<sub>2</sub>,  
 < GHYSLK(Chel)WKPG-NH<sub>2</sub>, NaI<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub>(Chel)WKPG-NH<sub>2</sub>,  
 < GHWSYK<sub>d</sub>(Chel)LRPG-NH<sub>2</sub>, AcNaI<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub>(Chel)LRPA<sub>d</sub>-NH<sub>2</sub>,  
 AcNaI<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub>(Chel)LRPA<sub>d</sub>-NH<sub>2</sub>, AcNaI<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub>(Chel)LRPA<sub>d</sub>-NH<sub>2</sub>,  
 < GHWSYK(Chel)LRPG-NH<sub>2</sub>, AcK(Chel)F<sub>d</sub>CFW<sub>d</sub>KTCT-OH, AcK(Chel)DF<sub>d</sub>CFW<sub>d</sub>KTCT-  
 OH, AcK(Chel)F<sub>d</sub>CFW<sub>d</sub>KTCT-ol, AcK(Chel)DF<sub>d</sub>CFW<sub>d</sub>KTCT-ol, (Chel)DF<sub>d</sub>CFW<sub>d</sub>KTCT-OH,  
 K(Chel)DF<sub>d</sub>CFW<sub>d</sub>KTCT-ol, K(Chel)KKF<sub>d</sub>CFW<sub>d</sub>KTCT-ol, K(Chel)KDF<sub>d</sub>CFW<sub>d</sub>KTCT-OH,  
 K(Chel)DSF<sub>d</sub>CFW<sub>d</sub>KTCT-OH, K(Chel)DF<sub>d</sub>CFW<sub>d</sub>KTCT-OH, K(Chel)DF<sub>d</sub>CFW<sub>d</sub>KTCD-NH<sub>2</sub>,  
 K(Chel)DF<sub>d</sub>CFW<sub>d</sub>KTCT-NH<sub>2</sub>, K(Chel)KDF<sub>d</sub>CFW<sub>d</sub>KTCT-NH<sub>2</sub>, AcK(Chel)F<sub>d</sub>CFW<sub>d</sub>KTCT-  
 NH<sub>2</sub>, K(Chel)F<sub>d</sub>CFW<sub>d</sub>KTCT-ol, and F<sub>d</sub>CFW<sub>d</sub>KTCTK(Chel)-NH<sub>2</sub>,  
 wherein (Chel) is said radiometal-binding moiety.

42. A method according to claim 24, wherein said peptide contains at least one disulfide bond.

43. A method according to claim 42, wherein said peptide is a polypeptide.

44. A method according to claim 42, wherein said peptide is a protein.

### Remarks

Claims 1-23 have been canceled and claims 24-44 have been added. The new claims are supported throughout the specification and claims. An Action on the merits is now awaited. Should there be any questions, the Examiner is courteously invited to contact the undersigned at the telephone number shown below.

Respectfully submitted,

October 2, 2000

Date

for Paul M. Booth 45,279  
Reg. No. 40,244

**FOLEY & LARDNER**  
3000 K Street, N.W.  
Suite 500  
Washington, D.C. 20007  
(202) 672-5300





Many tyrosine-containing peptides may be labeled with  $^{125}\text{I}$  by well known methods and used for receptor binding studies. For example, the incidence of VIP receptor upregulation has been studied *in vitro* in a wide range of cancer types using  $^{125}\text{I}$ -[Tyr $^{10}$ ]-VIP as the radioligand. See Reubi, *Nucl. Med.* 36:1846 (1995). The VIP receptor was detected in a wide variety of cancer types, including breast, prostate, ovarian, pancreatic, endometrial, bladder, colon, esophageal, SCLC, astrocytoma, glioblastoma, meningioma, pheochromocytoma, lymphoma, neuroblastoma adenoma, and GEP tumors. An iodinated VIP analogue  $^{123}\text{I}$ -[Tyr $^{10}$ ]-VIP has also been used to image VIP receptor-rich tumors in humans. See Virgolini *et al*, *supra*.

The use of radioiodine for *in vivo* diagnostic and therapeutic uses has distinct disadvantages, however.  $^{123}\text{I}$ , the most useful isotope *in vivo*, is very expensive (\$45.30/mCi) and must be produced in a cyclotron. This isotope, furthermore, has a half-life of only 13.2 hours, thereby requiring that it be produced in a geographic location close to where any radioiodinated imaging agent must be used. Other radioisotopes, such as  $^{99\text{m}}\text{Tc}$  and  $^{188}\text{Re}$  are preferred for diagnostic and therapeutic uses, respectively.  $^{99\text{m}}\text{Tc}$ , for example, is inexpensive (\$0.50/mCi), is readily available (produced in a generator from  $^{99}\text{Mo}$ , a reactor product), and has an ideal gamma emission energy for imaging with a gamma camera.

Some peptides either directly contain, or are amenable to the introduction of, residues that allow direct binding of radiometals such as  $^{99\text{m}}\text{Tc}$  and  $^{188}\text{Re}$  to the peptide. For example, somatostatin contains a disulfide bond that, upon reduction, provides two sulfhydryl-containing cysteine side chains that can directly bind  $^{99\text{m}}\text{Tc}$ . See U.S. Patent no. 5,225,180. See also WO 94/28942, WO 93/21962 and WO 94/23758. Complexes of this type tend, however, to be heterogeneous and unstable, which limits their clinical utility. Moreover, the use

of free sulfhydryls in this manner limits the radiometals which can be used to label the peptide to those that tightly bind free S-H groups. This method further suffers from the problem that direct binding of the metal to an amino acid side chain can greatly influence the peptide conformation, thereby deleteriously altering the receptor binding properties of the compound.

Most peptides either do not contain a metal-binding amino acid sequence motif or, for various reasons such as those described *supra*, are not amenable to suitable sequence modifications that would permit introduction of such a motif. Some means of rendering the peptide capable of binding radiometals must therefore be introduced into the peptide. A preferred approach is to attach a metal binding ligand to a specified site within the peptide so that a single defined, stable, complex is formed. The ligands used to bind metals often contain a variety of heteroatoms such as nitrogen, sulfur, phosphorous, and oxygen that have a high affinity for metals.

Chelates have conventionally been attached via covalent linkages to the N-terminus of a peptide or peptide analogue, following independent synthesis of the peptide and chelate moieties. For example, Maina et al. have described the coupling of a tetra-amine chelator to the N-terminus of a somatostatin analogue, allowing  $^{99m}\text{Tc}$  labeling of the peptide. See *J. Nucl. Biol. Med.* 38:452 (1994). Coupling in this manner is, however, undesirable when the N-terminus of the peptide plays an important role in its receptor binding properties. Accordingly, application of this method is limited by the requirement that the N-terminus of the peptide accommodate the presence of a (usually sterically bulky) chelator without deleteriously affecting the binding properties of the peptide.

Alternatively, chelating agents have been introduced into peptide side chains by means of site-selective reactions involving particular amino acid residues. For

example, the lysine residue at position 6 of LHRH has been directly acylated with a chelating group. See Bajusz, S. et al. *Proc. Natl. Acad. Sci. USA* 86:6313 (1989). This method is inherently limited by the lack of chemical selectivity available when more than one side chain can potentially react with the chelator, or when the peptide sequence does not contain an amino acid that can be derivatized in this way. A further limitation of this approach can arise when multidentate ligands are used. A single ligand molecule can react with multiple peptide molecules resulting in the formation of significant amounts of cross-linked products.

Chelating agents have been introduced on the side chain of a peptide through tris amino acids as described by Dunn T.J. et al. WO 94/26294. This method does not provide a method for cyclizing the peptides. The side chain protecting groups used to introduce the ligand described in this work are the same as those typically used for peptide amide cyclization. See Felix et al. *Int. J. Peptide Protein Res.* 32:441 (1988).

A fully protected BAT (bisaminothiol) chelating agent has been synthesized and coupled to the side chain of a lysine residue, which could then be incorporated into a peptide. See Dean et al. WO 93/25244. These fully protected precursors are very time consuming, expensive and cumbersome to prepare. The difficulty and expense of preparing such precursors make this method untenable for preparing a diverse array of ligands attached to the variety of linkers that is needed to design a metal carrying targeting agent.

One potential solution to this problem is to use a protecting group strategy that allows selective coupling of a chelator moiety to specified positions within a peptide chain. The diversity of chemical reactivities present within the amino acid side chains of a peptide has, however, led to difficulties in achieving sufficient selectivity in site-specific deprotection of protecting groups. This lack of selectivity has also heretofore

hampered efforts to selectively deprotect two or more different functional groups within a peptide to allow coupling of these groups in, for example, a cyclic peptide.

5        Edwards et al. *J. Med. Chem.* 37:3749 (1994) have disclosed a fragment method of assembling a cyclic disulfide on a resin with a subsequent attachment of an intact ligand (DTPA). This approach afforded the known somatostatin targeting agent DTPA-Octreotide. This approach was specifically designed for the preparation of a known compound. A more typical situation, however, requires that a variety of labeled peptides to optimize binding to a particular target. Such a situation requires, therefore, a broader approach allowing the assembly of multiple ligands, best assembled in fragments, placed at any point desired in a sequence which can also be cyclized at a variety of positions in the peptide sequence.

10        Additional considerations for the synthesis of peptides that can selectively bind metals include the effect of the chelate on the conformation of the peptide. Most peptides are highly conformationally flexible, whereas efficient receptor binding usually requires that a peptide adopt a specific conformation. Whether or not the peptide can adopt this specific conformation is greatly influenced by charge and hydrophilic/hydrophobic interactions, including the effects of a covalently attached metal chelating moiety. It is possible to enhance peptide receptor affinity and selectivity by restricting the conformations that the peptide can adopt, preferably locking the peptide into an active conformation. This is often most readily achieved by preparing cyclic peptides. Cyclic peptides have the added advantage of enhanced resistance to proteases, and therefore frequently demonstrate a longer biological half-life than a corresponding linear peptide.

35        Peptides can be cyclized by a variety of methods such as formation of disulfides, sulfides and, especially,


lactam formation between carboxyl and amino functions of the N- and C-termini or amino acid side chains. However, the plethora of functionality within a peptide chain typically means that, for all but the shortest peptides, selective coupling between two desired functional groups within a peptide is very difficult to achieve.

It is apparent, therefore, that cyclic peptides that can chelate metals ions while retaining the ability to specifically bind with high affinity to a receptor are greatly to be desired. It is also desirable to have a means of attaching a chelating moiety to any predetermined position within a peptide, and to have a means of selectively forming cyclic peptides between any two preselected positions within a peptide chain. Additionally, it is desirable to have access to a method that would allow a chelating moiety to be coupled to a peptide at any desired stage during peptide synthesis.

#### Summary of the Invention

It is therefore an object of the present invention to provide peptides that can bind radionuclides while retaining the ability to specifically bind to the peptide receptor. It is a further object of the invention to provide methods of preparing and radiolabeling peptides that can bind radionuclides while retaining the ability to specifically bind to the peptide receptor. It is a still further object of the invention to provide diagnostic and therapeutic methods of using the radiolabeled peptides to image or treat a tumor, an infectious lesion, a myocardial infarction, a clot, atherosclerotic plaque, or a normal organ or tissue.

In accomplishing the foregoing objects of the invention, there has been provided, in accordance with one aspect of the current invention, a peptide comprising a radiometal-binding moiety, wherein said binding moiety comprises the structure I:



where  $\text{R}^1$ ,  $\text{R}^2$ , and  $\text{R}^3$  independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, and a protecting group that can be removed under the conditions of peptide synthesis, provided that at least one of  $\text{R}^1$ ,  $\text{R}^2$ , or  $\text{R}^3$  is H.  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$  and  $\text{R}^{10}$  independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, aryl, and substituted aryl, or  $\text{R}^4$  and  $\text{R}^6$  together optionally form a direct bond.  $\text{R}^8$  and  $\text{R}^9$  together or  $\text{R}^7$  and  $\text{R}^9$  together may form a cycloalkyl or substituted cycloalkyl ring, and  $\text{NR}^{10}$  is located at the N-terminus of said peptide, or is located on an amino acid side chain of said peptide.

In preferred embodiments of the invention,  $\text{R}^1$  is H,  $\text{R}^3$  is H,  $\text{R}^4$  is H, or  $\text{R}^4$  and  $\text{R}^6$  together form a direct bond. In other preferred embodiments,  $\text{R}^2$  is lower alkyl or substituted or unsubstituted phenyl, or more preferably methyl or phenyl. In other preferred embodiments,  $\text{R}^8$  and  $\text{R}^9$  are methyl.

In accordance with another aspect of the invention, the peptides further comprise a bound metal atom. In preferred embodiments the metal atom is  $^{99\text{m}}\text{Tc}$ ,  $^{186}\text{Re}$ , or  $^{188}\text{Re}$ .

In accordance with yet another aspect of the invention, there is provided a method of preparing a metal-chelating composition, where a solution of a peptide comprising a radiometal-binding moiety is contacted with stannous ions, where the binding moiety has the structure set forth above, followed by contacting the solution with a radionuclide, and recovering the radiolabeled peptide. In a preferred embodiment of the method the radionuclide is <sup>188</sup>Re- or <sup>186</sup>Re-perrhenate or <sup>99</sup>Tc-pertechnetate.

In accordance with still another aspect of the invention, there is provided a method of imaging a tumor, an infectious lesion, a myocardial infarction, a clot, atherosclerotic plaque, or a normal organ or tissue, comprising administering to a human patient a radiolabeled peptide, together with a pharmaceutically acceptable carrier, and, after a sufficient time for said radiolabeled peptide to localize and for non-target background to clear, the site or sites of accretion of said radiolabeled peptide are detected by an external imaging camera, where the radiolabeled peptide is prepared by contacting a solution of a peptide with stannous ions, where the peptide comprises a radiometal-binding moiety having the structure set forth above, and then contacting said solution with a radionuclide and recovering the radiolabeled peptide.

In accordance with another aspect of the invention there are provided peptides having a structure selected from the group consisting of:

(Chel)γAbuNleDHF<sub>4</sub>RWK-NH<sub>2</sub>,  
(Chel)γAbuHSDAVFTDNYTRLRKQMAVKKYLNSILN-NH<sub>2</sub>,  
KPRRPYTDNYTRLRK(Chel)QMAVKKYLNSILN-NH<sub>2</sub>,  
(Chel)γAbuVFTDNYTRLRKQMAVKKYLNSILN-NH<sub>2</sub>,  
(Chel)γAbuYTRLRKQMAVKKYLNSILN-NH<sub>2</sub>,  
HSDAVFTDNYTRLRK(Chel)QMAVKKYLNSILN-NH<sub>2</sub>,  
<GHWSYK(Chel)LRPG-NH<sub>2</sub>, <GHYSLK(Chel)WKPG-NH<sub>2</sub>,  
AcNal<sub>4</sub>Cpa<sub>4</sub>W<sub>4</sub>SRK<sub>4</sub>(Chel)LRPA<sub>4</sub>-NH<sub>2</sub> ,



(Chel) $\gamma$ AbuSYSNleDHF<sub>d</sub>RWK-NH<sub>2</sub>, (Chel) $\gamma$ AbuNleDHF<sub>d</sub>RWK-NH<sub>2</sub> ,  
(Chel)NleDHF<sub>d</sub>RWK-NH<sub>2</sub> ,  
Ac-HSDAVFTENYTKLRK(Chel)QNleAAKKYLNDLKKGGT-NH<sub>2</sub>,  
(Chel) $\gamma$ AbuHSDAVFTDNYTRLRKQMAVKKYLNSILN-NH<sub>2</sub>,  
5 (Chel) $\gamma$ AbuVFTDNYTRLRKQMAVKKYLNSILN-NH<sub>2</sub>,  
(Chel) $\gamma$ AbuNleDHF<sub>d</sub>RWK-NH<sub>2</sub><sup>c</sup>, <GHWSYK(Chel)LRPG-NH<sub>2</sub>,  
<GHYSLK(Chel)WKPG-NH<sub>2</sub>, AcNal<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub>(Chel)LRPA<sub>d</sub>-NH<sub>2</sub>,  
<GHYSLK(Chel)WKPG-NH<sub>2</sub>, <GHYSLK(Chel)WKPG-NH<sub>2</sub>,  
Nal<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub>(Chel)WKPG-NH<sub>2</sub>, <GHWSYK<sub>d</sub>(Chel)LRPG-NH<sub>2</sub>,  
10 AcNal<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub>(Chel)LRPA<sub>d</sub>-NH<sub>2</sub>,  
AcNal<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub>(Chel)LRPA<sub>d</sub>-NH<sub>2</sub>,  
AcNal<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub>(Chel)LRPA<sub>d</sub>-NH<sub>2</sub>, <GHWSYK(Chel)LRPG-NH<sub>2</sub>,  
AcK(Chel)F<sub>d</sub>CFW<sub>d</sub>KTCT-OH, AcK(Chel)DF<sub>d</sub>CFW<sub>d</sub>KTCT-OH,  
AcK(Chel)F<sub>d</sub>CFW<sub>d</sub>KTCT-ol, AcK(Chel)DF<sub>d</sub>CFW<sub>d</sub>KTCT-ol,  
15 (Chel)DF<sub>d</sub>CFW<sub>d</sub>KTCT-OH, K(Chel)DF<sub>d</sub>CFW<sub>d</sub>KTCT-ol,  
K(Chel)KKF<sub>d</sub>CFW<sub>d</sub>KTCT-ol, K(Chel)KDF<sub>d</sub>CFW<sub>d</sub>KTCT-OH,  
K(Chel)DSF<sub>d</sub>CFW<sub>d</sub>KTCT-OH, K(Chel)DF<sub>d</sub>CFW<sub>d</sub>KTCT-OH,  
K(Chel)DF<sub>d</sub>CFW<sub>d</sub>KTCD-NH<sub>2</sub>, K(Chel)DF<sub>d</sub>CFW<sub>d</sub>KTCT-NH<sub>2</sub>,  
K(Chel)KDF<sub>d</sub>CFW<sub>d</sub>KTCT-NHNH<sub>2</sub>, AcK(Chel)F<sub>d</sub>CFW<sub>d</sub>KTCT-NHNH<sub>2</sub>,  
20 K(Chel)F<sub>d</sub>CFW<sub>d</sub>KTCT-ol, and F<sub>d</sub>CFW<sub>d</sub>KTCTK(Chel)-NH<sub>2</sub>,  
wherein (Chel) is a radiometal-binding moiety having the  
structure set forth above.


Other objects, features and advantages of the present  
invention will become apparent from the following  
25 detailed description. It should be understood, however,  
that the detailed description and the specific examples,  
while indicating preferred embodiments of the invention,  
are given by way of illustration only, since various  
changes and modifications within the spirit and scope of  
30 the invention will become apparent to those skilled in  
the art from this detailed description.

#### Detailed Description

The present invention provides new chelating moieties  
that can be covalently linked to peptides, cyclic  
35 peptides and peptide analogues. The chelating moieties  
allow the peptides, cyclic peptides and peptide analogues

to stably bind metals, especially radiometals. Methods of preparing these chelators, peptides and peptide analogues are also provided. The peptides and peptide analogues are prepared by site-specifically introducing the metal-chelating moieties into peptides that are synthesized by solid-phase or solution phase methods. The chelating moieties may be attached to an amine-bearing side-chain of an amino acid within the peptide chain, or may be attached to the N-terminus of the peptide. Peptides according to the invention include, but are not limited to, cyclic metal-binding analogues of LHRH, vasoactive intestinal peptide (VIP), heregulins (erbB binding peptides)  $\alpha$ ,  $\beta 1$ ,  $\beta 2$ , and  $\beta 3$ , melanotropin ( $\alpha$ -MSH), somatostatin, calcitonin, epidermal growth factor, gonadotrophin releasing hormone, heregulins growth hormone releasing hormone, dynorphin, calcitonin gene-related peptide, vasotocin, mesotonin, adrenocorticotrophic hormone, corticotropin, gonadotropin, prolactin, vasopressin, oxytocin, substance P, substance K, and angiotensin.

The chelating moieties may be represented by the general formula I:



where  $\text{R}^1$ ,  $\text{R}^2$ , and  $\text{R}^3$  independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, and a protecting group that can be removed under the conditions of peptide synthesis. At least one of  $\text{R}^1$ ,  $\text{R}^2$ , or  $\text{R}^3$  must be H.  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$  and  $\text{R}^{10}$  independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, aryl, and substituted aryl.  $\text{R}^4$  and  $\text{R}^6$  together also may optionally form a direct bond, and  $\text{R}^5$  and  $\text{R}^9$  together or  $\text{R}^7$  and  $\text{R}^9$  together also may form a cycloalkyl

or substituted cycloalkyl ring.  $\text{NR}^{10}$  is located at the N-terminus of the peptide to which the chelator is attached, or is located on an amino acid side chain of that peptide. When  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^5$ , or  $\text{R}^6$  bears a heteroatom substituted function, the heteroatom also may be used to carry out additional peptide coupling reactions.

Examples of lower alkyl include, but are not limited to, straight or branched chain  $\text{C}_1$ - $\text{C}_6$  alkyl groups, such as a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, and n-hexyl. Cycloalkyl includes  $\text{C}_3$ - $\text{C}_6$  cycloalkyl, such as cyclohexyl. Heterocycloalkyl includes tetrahydrofuran, tetrahydropyran, pyrrolidine, and piperidine. Heteroaryl includes pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, oxazolylthio, thiazolyl, pyrazolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, morpholinyl, and piperizinyl. Aryl includes  $\text{C}_6$ - $\text{C}_{12}$  aryl such as phenyl,  $\alpha$ -naphthyl, or  $\beta$ -naphthyl.

Alkaryl includes:  $\text{C}_6$ - $\text{C}_{12}$ aryl $\text{C}_1$ - $\text{C}_6$ alkyl, such as phenyl $\text{C}_1$ - $\text{C}_6$ alkyl, or  $\alpha$ - or  $\beta$ -naphthyl $\text{C}_1$ - $\text{C}_6$ alkyl, such as benzyl, phenylethyl, phenylpropyl, phenylbutyl, phenylpentyl,  $\alpha$ - or  $\beta$ -naphthylmethyl, naphthylethyl, naphthylpropyl, naphthylbutyl, or naphthylpentyl.

Examples of substituent groups include:  $\text{C}_1$ - $\text{C}_6$  alkoxy, for example, methoxy, ethoxy, propoxy;  $\text{C}_1$ - $\text{C}_6$  alkylthio, for example methylthio, ethylthio, propylthio;  $\text{C}_6$ - $\text{C}_{12}$ aryl $\text{C}_1$ - $\text{C}_6$ alkoxy, for example phenyl $\text{C}_1$ - $\text{C}_6$  alkoxy such as benzyloxy; aralkylthio, for example phenyl $\text{C}_1$ - $\text{C}_6$ alkylthio such as benzylthio; amino, substituted amino, for example  $\text{C}_1$ - $\text{C}_6$ alkylamino such as methylamino, ethylamino;  $\text{C}_6$ - $\text{C}_{12}$ aryl $\text{C}_1$ - $\text{C}_6$ alkyl, such as phenyl $\text{C}_1$ - $\text{C}_6$  alkyl for example benzyl;  $\text{C}_6$ - $\text{C}_{12}$ aryl such as phenyl;  $\text{C}_3$ - $\text{C}_8$  cycloalkyl such as cyclohexyl; and  $\text{C}_3$ - $\text{C}_8$  cycloalkyl $\text{C}_1$ - $\text{C}_6$ alkyl such as cyclohexylmethyl.

Preferred embodiments of the invention include compounds where  $\text{R}^2$  is H, methyl, or phenyl, and where  $\text{R}^8$

and R<sup>9</sup> are methyl. Other preferred embodiments are where R<sup>1</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>7</sup> and R<sup>10</sup> are H.

The peptides may be synthesized using differentially protected bis-amino acid derivatives in which either amino function can be selectively deprotected. These derivatives are introduced into a growing peptide chain during peptide synthesis by conventional peptide coupling methodology. One of the amino functions is then selectively deprotected, allowing subsequent coupling of either all or a part of a chelating molecule, or addition of further amino acid residues to continue the peptide synthesis. Peptide synthesis can be continued by coupling at the  $\alpha$ -amino group, leading to a peptide with a conventional amide backbone, or at the side-chain amino group to produce a peptide whose amide backbone is interrupted by the side chain structure. Alternatively, the free amino function can be used to cyclize onto a reactive functionality located elsewhere in the peptide, thereby producing a cyclic peptide. Suitable bis-amino acids will be readily apparent to the skilled practitioner, and include lysine, ornithine, and 2,3-diaminopropionic acid (amino-serine). Alternatively, the chelating moiety may be introduced at the end of peptide synthesis by coupling the chelating moiety to the deprotected N-terminus of the resin-bound peptide. The chelating moiety may be added as a complete unit, in protected or unprotected form, or may be synthesized in stepwise fashion to construct the complete chelating structure.

Bis-amino acids used in the present invention may be generally represented by the formula:  $ZHN-CH(-R-NHY)-CO_2H$  where R is  $(CH_2)_n$  or  $(CH_2)_n-X-(CH_2)_n$  where X is a heteroatom such as O, S, or N and  $n=1-20$ . Alternatively the hydrogen atoms of the  $CH_2$  groups can be replaced with lower alkyl, substituted lower alkyl, or alkenyl groups, or cyclic or heterocyclic rings such as cyclohexane, benzene, and piperidine, or other groups well known to the skilled artisan. The substituents Z and Y independently can be

H, N, lower alkyl, substituted lower alkyl, aryl, or substituted aryl.

5 If peptide synthesis is continued, selective deprotection of the second amino group of the bis-amino acid can be accomplished at any point during the peptide synthesis to introduce the chelating moiety. The complete chelating moiety can be synthesized prior to coupling to the peptide, or it can be synthesized by sequentially coupling segments to the peptide. Once assembly of the entire peptide/chelator structure is complete, cleavage, deprotection, and purification affords the desired peptide derivative. This derivative is then labeled with a radiometal for use in radiodiagnostic and radiotherapeutic applications.

10 Alternatively, if all or part of the chelating molecule is coupled to the deprotected amino group first, the second step is to deprotect the other amino group and continue with the peptide synthesis. If only part of the chelator moiety is coupled to the peptide at this stage, the synthesis of the chelator can be finished at any point during or after synthesis of the peptide chain by appropriate deprotection and coupling reactions. Final cleavage, deprotection and purification steps once again yield the pure peptide derivative, which is then radiolabeled as before.

25 Attachment of the chelator to the peptide prior to cleavage from the resin results in reduced formation of cross-linked products even when multidentate activated chelators such as DTPA-dianhydride are used.

30 Preparation of cyclic peptides is achieved by selective deprotection of two compatible functional moieties at specified positions of the peptide sequence, followed by cyclization between the compatible moieties. Cyclization can be achieved between any two points of the peptide sequence, including between the N- and C-termini, between a terminus and an internal functional group within the peptide sequence, or between two internal functional groups. Cyclization can be achieved using

either solution-phase or solid-phase peptide syntheses, but is preferably carried out using solid-phase techniques.

5 The deprotection and cyclization can be carried out at any point during the synthesis of the peptide prior to the final deprotection reactions. For example, the entire protected peptide sequence can be prepared prior to the cyclization, or the cyclization can be carried out on a protected peptide intermediate, followed by completion of the synthesis. Similarly, the cyclization can be carried out either before or after all or part of the metal chelating moiety is coupled to the peptide. Use of a photocleavable or other resin known to those skilled in the art on a solid phase peptide synthesizer also allows release of a protected peptide from a solid support, with subsequent solution phase selective deprotection and cyclization. Alternatively, the side chains to be cyclized can be selectively deprotected prior to cleavage from the resin, and the cyclization carried out in solution phase.

10 Reactions involving the C-terminus of the peptide, including but not limited to cyclization reactions, may be accomplished through the release of a protected peptide from the resin in the manner described above. Alternatively, the growing peptide chain may be attached to the resin via the side chain of a residue and the C-terminal carboxyl group suitably protected. When a reaction with the C-terminal carboxyl group is desired, it is selectively deprotected and the reaction allowed to proceed. In the case of cyclization reactions, the deprotection of the C-terminus can be accomplished before, during, or after the selective deprotection of the compatible reactive group.

20 Reactions involving the C-terminus of the peptide, including but not limited to cyclization reactions, may be accomplished through the release of a protected peptide from the resin in the manner described above. Alternatively, the growing peptide chain may be attached to the resin via the side chain of a residue and the C-terminal carboxyl group suitably protected. When a reaction with the C-terminal carboxyl group is desired, it is selectively deprotected and the reaction allowed to proceed. In the case of cyclization reactions, the deprotection of the C-terminus can be accomplished before, during, or after the selective deprotection of the compatible reactive group.

25 The radiometal chelating peptides of the present invention stably retain radionuclide in blood and other bodily fluids and tissues. Both the reagents and the conditions in the present method are greatly simplified over those in the prior art, and the labeled peptides are

30

35

particularly suitable for radiodiagnostic and radiotherapy applications using technetium or rhenium labeling.

5 The approach outlined above allows the placement of a radiometal-binding moiety anywhere in a peptide sequence. Placing the chelating moiety on an amino acid side-chain, either directly or via a spacer group, rather than on the N-terminus of a peptide, has the added advantage of spatially distancing the metal complex from the peptide backbone, thereby minimizing the effect of the metal complex on the peptide conformation. This also allows the N-terminus of the peptide to be used for cyclizing the peptide, if necessary.

10 It is known that peptide conformation is greatly influenced by charge and hydrophilic/hydrophobic interactions, and it is therefore important to consider these variables when designing a chelating ligand to be used in peptides. It is preferred that a variety of chelating complexes of varying charge and hydrophilicity and containing spacer groups of various lengths are prepared and tested to select the metal-complexed peptide that displays the optimum combination of target selectivity, pharmacokinetics, and chelate stability. The skilled artisan will appreciate that such testing is routine in the art.

25 The radiolabeled peptides of the present invention bind specifically to a diseased cell or tissue that exhibits both a high receptor density and high affinity for the peptide. The radioactivity of the radionuclide allows diagnosis and/or treatment of the tumor or diseased tissue. The invention also includes pharmaceutical compositions comprising an effective amount of at least one of the radiolabeled peptides of the invention, in combination with a pharmaceutically acceptable sterile vehicle, as described, for example, in Remington's Pharmaceutical Sciences; Drug Receptors and Receptor Theory, 18th ed., Mack Publishing Co., Easton, PA (1990). The invention also includes kits for labeling

peptides which are convenient and easy to use in a clinical environment.

5      A.    Design    and    Synthesis    of    Linear    Peptides  
         Incorporating Chelating Moieties

         (i)    In General

         The peptides of the invention contain radiometal-  
chelating amino acid derivatives that are characterized  
by the presence of at least one thiol or thiocarbonyl  
10      group, and at least one nitrogen present as either a  
tertiary amine, a hydrazone, or a secondary amide or  
hydrazide. The sulfur and nitrogen atoms are suitably  
disposed to form a multidentate ligand capable of tightly  
and preferentially binding a metal ion. The multidentate  
15      ligand may also contain a spacer group that serves to  
separate the chelated metal from the rest of the peptide.  
The metal ion is preferably a reduced radionuclide, and  
in a preferred embodiment is  $^{99m}\text{Tc}$ ,  $^{186}\text{Re}$ , or  $^{188}\text{Re}$ .

         The invention also provides a method for placing  
20      ligands for other metals at any point in a peptide  
sequence. These ligands can be introduced intact, for  
example DTPA, or as fragments. In this way ligands for  
other metals of medical interest including, but not  
limited to, In, Ga, Y, Cu, Pt, Mn, Gd, Au, Ag, Hg, and Lu  
25      can be placed in a peptide targeting sequence.

         The method allows the introduction of any metal  
chelate or chelate fragment that is suitably protected  
for peptide synthesis. The method also provides a method  
for the introduction of base-sensitive ligand derivatives  
30      that can be placed at any point in the peptide sequence  
as long as it is introduced at the end of the synthesis.  
An example is the synthesis of a ligand attached to the  
side chain of lysine using the following ligand fragment  
Trityl-S-COCH<sub>2</sub>N(Boc)CH<sub>2</sub>CO<sub>2</sub>H. The S-Trityl ester will be  
35      sensitive towards base so it would not be possible to  
place this ligand fragment on the peptide at an earlier  
point in the synthesis.



Each of the chelating moieties of the invention can be prepared by methods well known to the skilled practitioner in the art of organic synthesis. The chelating moieties are constructed from subunits that are linked together by simple coupling or condensation reactions, such as the condensation of an amino, hydrazino, or hydrazido function with an activated carboxyl group, coupling of hydrazines with aldehydes, or reductive amination reactions between amines and aldehydes. As used herein the term "condensation" is intended to encompass reactions that couple together subunits of the chelating moiety, and thus encompasses reactions such as reductive amination in addition to reactions that conform to the classical definition of a condensation reaction.

Following a condensation reaction, additional functional groups on the subunit may be deprotected to allow additional condensation reactions. For example, a second subunit carrying a free carboxyl group and a protected amino function can be condensed with an amino, hydrazino, or hydrazido function on a first subunit to produce a larger, suitably protected fragment of the metal binding ligand. The amino function on the second subunit moiety can then be deprotected and further coupled to a third subunit. As used herein, the term "fragment" is intended to encompass a subunit or assembly of subunits comprising all or part of the metal binding ligand.

Methods of activating carboxyl groups for such condensation reactions are well known to those of skill in the art of organic synthesis and peptide synthesis, and include the use of active esters and of carbodiimide and phosphoryl azide coupling agents. Suitable protecting groups are used for protecting functions on the subunits when the reactivity of the functions is incompatible with a reaction used to join the subunits or with reactions used for synthesis of the peptide chain. Protecting groups for mercapto, amino and carboxylic acid

functions are well known in the art. See, for example, Greene, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS (Wiley Interscience, NY, 1981). The subunits used to construct the chelate are either readily prepared by methods well known in the art, or are commercially available from suppliers such as Advanced ChemTech (Lexington, KY), Milligen (Burlington, MA), Applied Biosystems (Foster City, CA), or Aldrich Chemical Corp. (Milwaukee, WI).

The condensation reactions used to link together the chelator subunits can either be carried out prior to peptide synthesis, or during synthesis of the peptide sequence. When the amino acid derivative is assembled from its subunits prior to peptide synthesis,  $\alpha$ -amino and  $\alpha$ -carboxyl functions must be suitably protected in a manner that is subsequently compatible with selective deprotection and activation of these functionalities for peptide synthesis. Examples of such protecting groups are well known in the art, and include the fluorenylmethyloxycarbonyl (Fmoc), benzyloxycarbonyl (Cbz), *t*-butoxycarbonyl (Boc), allyloxycarbonyl (alloc), 4-methoxytrityl (mtt), and 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (Dde) groups for amino protection. Groups for carboxyl protection include the methyl (Me), benzyl (Bn), *t*-butyl (Bu), and allyl esters, respectively.

The amino and carboxyl protecting groups must be selected such that each group can be selectively deprotected in the presence of the other. Such protecting moieties are said to be orthogonal. The requirement that orthogonal protecting groups be used precludes, for example, use of the Cbz group for protection of the amino function in the presence of a carboxyl group protected as a benzyl ester. See Greene, *supra*. In a preferred embodiment the  $\alpha$ -amino group is protected as an Fmoc group, and the  $\alpha$ -carboxyl group is a methyl ester. The thiol protecting group used in the compounds of the invention can be any organic or inorganic group which is readily removed under mild

conditions to regenerate the free sulfhydryl in the presence of the peptide without substantially altering the activity of the protein. Suitable protecting groups are listed in Greene, *supra*, pp. 193-217. Examples of suitable protecting groups include substituted and unsubstituted trityl groups, thiol esters, thiocarbamates and disulfides. In a preferred embodiment the thiol protecting group is a trityl group or a 4-methoxytrityl group. Those skilled in the art are familiar with the procedures of protecting and deprotecting thiol groups. For example, benzoate thioesters may be deprotected under mild and selective conditions using hydroxylamine. Once assembly of the protected chelating moiety is complete, the  $\alpha$ -carboxy function is deprotected and coupled to the amino terminus of the peptide chain using conventional methods of peptide synthesis. See Bodanszky et al., THE PRACTICE OF PEPTIDE SYNTHESIS (Springer Verlag, Heidelberg, 1984).

When the metal-chelating amino acid derivative is assembled from its subunits during peptide synthesis, the peptide chain is assembled by conventional solution phase or, preferably, solid phase synthesis until the point where the derivative is to be incorporated. The differentially protected bis-amino acid is then coupled to the amino terminus of the peptide chain. Subsequent selective deprotection of one of the amino groups of the derivative allows either peptide synthesis or chelator synthesis to continue.

If the  $\alpha$ -amino function is deprotected first, all or part of the remaining amino acid residues are then coupled to the peptide chain in the conventional manner. The side chain amino function of the derivative is then deprotected, and the chelating moiety is assembled as described above. The complete peptide can then be deprotected and purified by standard methods.

If the side chain amino function is deprotected first, all or part of the chelating moiety is then assembled as described above, followed by deprotection of

the  $\alpha$ -amino group. Peptide synthesis is completed in the conventional manner as described above.

Once peptide synthesis is complete the fully protected peptide is deprotected and purified. Methods for deprotection and purification of synthetic peptides are well known in the art. See, for example, Bodanszky, *supra*. If the peptide was synthesized by solid phase techniques the peptide must also be cleaved from the resin used as the solid support for the synthesis. Methods for achieving this cleavage also are well known in the art. Methods for purifying synthetic peptides such as those of the present invention also are well known to those of skill in the art. Such methods include, for example, ion exchange, gel filtration chromatography, and reversed phase high pressure liquid chromatography (RP-HPLC). In a preferred embodiment of the invention the peptide is purified by RP-HPLC using a preparative-scale octadecylsilane (C18) silica column packing, eluting with a gradient of acetonitrile in 0.1% trifluoroacetic acid (TFA). The purity of the peptide can be confirmed by standard methods such as analytical RP-HPLC or capillary electrophoresis. The identity of the peptide can be confirmed by NMR spectroscopy or, in a preferred embodiment of the invention, by mass spectrometry.

As noted above, it is important that the chelating moiety does not interfere with peptide binding to the appropriate receptor. Determining the residues within the peptide that can be replaced without deleteriously affecting receptor binding can be carried out in a systematic and straightforward way by preparing a series of peptides in which each successive residue is replaced with, for example, alanine, (an "alanine scan"). The alanine-substituted peptides then are screened for biological activity. Modern peptide synthesizers make synthesis of peptides in this way quite straightforward, and screening of a large number of peptides is routine for the skilled artisan. Retention of high receptor


binding affinity in a peptide containing such an alanine substitution denotes that the substituted amino acid is less important for receptor binding, and indicates a position where the metal-binding residue may be placed.

5 Synthesis of peptides wherein a chelator is placed in each of these positions is then straightforward, and routine screening establishes the optimal position for the chelator.

As set forth above, a wide variety of peptides containing metal binding ligands may be prepared using the methods of the present invention. Additional methods of preparing metal chelating peptides using the methods of the claimed invention will be apparent to the skilled artisan. Specific applications using these methods are set forth below to further exemplify the invention, but it will be appreciated that these examples are merely illustrative and are not meant to limit the scope of application of the invention.

#### (ii) Preparation of chelating moieties

20 In a preferred embodiment, the chelator contains a thiol group together with a thiosemicarbazide or thiosemicarbazone group, and can be represented by the general formula I:



where  $R^1$ ,  $R^2$ , and  $R^3$  independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, and a protecting group that can be removed under the conditions of peptide synthesis. At least one of  $R^1$ ,  $R^2$ , or  $R^3$  must be H.  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$  and  $R^{10}$  independently are selected from the group consisting of H, lower alkyl, substituted lower

alkyl, aryl, and substituted aryl.  $R^4$  and  $R^6$  together also may optionally form a direct bond, and  $R^8$  and  $R^9$  together or  $R^7$  and  $R^9$  together also may form a cycloalkyl or substituted cycloalkyl ring.  $NR^{10}$  is located at the N-terminus of the peptide to which the chelator is attached, or is located on an amino acid side chain of that peptide. When  $R^1$ ,  $R^2$ ,  $R^5$ , or  $R^6$  bears a heteroatom substituted function, the heteroatom also may be used to carry out additional peptide coupling reactions.

Although an understanding of the mechanism of metal binding by the chelating moieties is not necessary for practicing the invention, and without wishing to be bound by any theory, it is believed that the metal is bound to the chelator via the two sulfur atoms plus two nitrogen atoms. It is hypothesized that the metal-binding nitrogens are the  $\alpha$ -nitrogen of the  $\beta$ -thiol-containing amino acid and the thiocarbazide/thiocarbazone nitrogen distal to the thiocarbonyl group. When the metal is reduced radioperrhenate or reduced radiopertechetate, the two sulfur and two nitrogen atoms provide four coordination positions on the metal.

These compounds may be prepared by methods that are well known in the art of organic synthesis. Thus, for example, compounds having formula I may be prepared by amide coupling between an  $\alpha$ -carboxyl-protected amino acid moiety having a protected or unprotected  $\beta$ -thiol-containing side chain (a "cysteine-type amino acid"), and a carboxyl-containing thiosemicarbazone or thiosemicarbazide moiety. This coupling can be carried out using well-known methods, such as carbodiimide-mediated coupling. Deprotection of the  $\alpha$ -carboxyl group of the amino acid allows amide coupling of the chelating moiety to an amino side chain, or the amino terminus, of the peptide. Alternatively, an N- and S-protected cysteine-type amino acid having a  $\beta$ -thiol containing side chain may first be coupled to the peptide, followed by N-deprotection and amide coupling to a carboxyl-containing thiosemicarbazone or thiosemicarbazide moiety.

Cysteine-type amino acids may be prepared by standard methods of amino acid synthesis. The configuration at the  $\alpha$ -carbon may be (R) or (S), or the amino acid may be racemic. Similarly, the configuration at the  $\beta$ -carbon, when asymmetrically substituted may be (R), (S), or (R/S). The amino acid is protected for subsequent coupling reactions using standard methods.

Thiosemicarbazones may be prepared by the condensation of semicarbazides with carbonyl compounds. Reduction of the thiosemicarbazones with, for example, sodium borohydride, provides substituted thiosemicarbazides. In a preferred embodiment, a thiosemicarbazide is reacted with glyoxylic acid to form the corresponding thiosemicarbazone, which optionally may be reduced to form a substituted thiosemicarbazide.

Many thiosemicarbazides are commercially available from, for example, Aldrich Chemical Company, Milwaukee, WI. Other thiosemicarbazides may be prepared by the reaction of a hydrazine with, for example, an isothiocyanate. Asymmetrically substituted hydrazines also are commercially available, or may be prepared by nitrosation of amines to the nitrosamine, followed by reduction to the hydrazine. Isothiocyanates may be prepared by reaction of an amine with thiophosgene. Other methods of preparing thiosemicarbazides are well known to the skilled artisan.

In some instances, it is found that thiosemicarbazides have low solubility in the solvents used for coupling to the cysteine-like amino acid. In such instances, the coupling can be carried out using the thiosemicarbazone, followed by coupling to the peptide. The thiosemicarbazone then may be reduced to the thiosemicarbazide using sodium borohydride or another suitable reducing agent. When the thiosemicarbazide is sufficiently soluble to be used directly, the  $\alpha$ -nitrogen must first be protected prior to coupling. Suitable protecting groups are well known in the art and include Boc and Cbz groups.


(iii) Linear VIP Receptor Targeting Agents

Naturally occurring VIP has the sequence:



An alanine scan has revealed several residues whose replacement with alanine does not greatly affect receptor binding. These residues include Lys-15, Gln-16, Val-19, Lys-21, Asn-24, Ser-25 and the N- and C-termini. These locations are possible sites for the attachment of a metal binding ligand according to the present invention.

Chelating derivatives based on attachment of the metal binding ligand at these positions include, but are not limited to, those with a metal binding moiety attached, either directly or via a spacer group, to the pharmacophore via the side chain amine of a lysine or other bis-amino acid residue. Specific chelating derivatives of this general structure include, but are not limited to:



where Ma is mercaptoacetic acid,

PtscG is 2-(4-phenyl-3-thiosemicarbazidyl)acetic acid or  $\text{PhNHCSNHNHCH}_2\text{CO}_2\text{H}$ ,

$\gamma\text{Abu}$  is  $\gamma$ -aminobutyric acid, and

in  $\text{K(PtscGC)}$ , the parentheses denote that enclosed amino acids are attached to the  $\epsilon$  amine of lysine and the first amino acid attached is C followed by PtscG.

In each of the compounds described above, the chelating moiety may be replaced by a chelator of the general formula I, as described above.




(iv) Linear LHRH Receptor Targeting Agents

Naturally occurring LHRH has the sequence:






where <G is pyroglutamic acid. It is further known that  
5 the bicyclic peptide



(where  $W_d$  indicates that the D isomer of the amino acid  
was used, Nal is 2-naphthylalanine, Cpa is 4-  
chlorophenylalanine and Dap is 2,3-diaminopropionic acid)  
10 binds to the LHRH receptor. See Bienstock et al. *J. Med.*  
*Chem.* 36:3265 (1993). It is also known that the side  
chain of position 6 of LHRH is very bulk tolerant. See  
Barbacci et al. *J. Biol. Chem.* 270:9585 (1995). This  
location is a possible site for the attachment of a metal  
15 binding ligand according to the present invention.

Linear chelating derivatives based on attachment of  
the metal binding ligand at this position include, but  
are not limited to, those with a metal binding moiety  
attached, either directly or via a spacer group, to the  
20 pharmacophore via the side chain amine of a lysine or  
other bis-amino acid residue. Specific linear chelating  
derivatives of these general structures include, but are  
not limited to:



<GHWSYK<sub>d</sub>(MtaGDap)LRPG-NH<sub>2</sub>  
 <GHWSYK<sub>d</sub>(PtscGC)LRPG-NH<sub>2</sub>  
 <GHWSYK<sub>d</sub>(E)LRPG-NH<sub>2</sub>  
 <GHWSYK<sub>d</sub>(MtscGC)LRPG-NH<sub>2</sub>  
 5 <GHWSYK<sub>d</sub>(Mta(hqss)GDap)LPG-NH<sub>2</sub>  
 AcNal<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub>(MaGC)LRPA<sub>d</sub>-NH<sub>2</sub>  
 Nal<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub>(PtscGC)LRPA<sub>d</sub>-NH<sub>2</sub>  
 AcNal<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub>(MaFC)LRPA<sub>d</sub>-NH<sub>2</sub>  
 AcNal<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub>(azaGFC)LRPA<sub>d</sub>-NH<sub>2</sub>

10 where:

<G is pyroglutamic acid,  
 Ma is mercaptoacetic acid  
 azaG is azaglycine or H<sub>2</sub>NNHCH<sub>2</sub>CO<sub>2</sub>H,  
 PtscG is 2-(4-phenyl-3-thiosemicarbazidyl)acetic  
 15 acid or PhNHCSNHNHCH<sub>2</sub>CO<sub>2</sub>H,  
 Dap is 2,3-diaminopropionic acid  
 iD is an aspartic acid coupled via the side chain  
 carboxyl group,  
 iE is a glutamic acid coupled via the side chain  
 20 acid group,  
 DiGly is HOOCCH<sub>2</sub>NHCH<sub>2</sub>COO- ,  
 Mta(hqss) is S-(2,5-dihydroxyphenyl-S-  
 methyl)sulfoniumacetyl  
 C<sub>a</sub> is an AcM protected cysteine  
 25 Mta is the methylthioether of mercaptoacetic acid,  
 Nal is 2-naphthylalanine,  
 Cpa is 4-chlorophenylalanine,  
 in K<sub>d</sub>, the subscript d denotes that the D isomer was  
 used, and  
 30 in K(MaGC), the parentheses denote that enclosed  
 amino acids are attached to the ε amine of  
 lysine and the first amino acid attached is C  
 followed by G and ending in Ma.

35 Additionally, complexes of these peptides with non-  
 radioactive metals may be prepared. Such complexes  
 include:

<GHWSYK(MaGC)LRPG-NH<sub>2</sub> ReO

<GHYSLK(MaGC)WKPG-NH<sub>2</sub> ReO

<GHYSLK<sub>d</sub>(MaGC)LRPG-NH<sub>2</sub> ReO

In each of the compounds described above, the chelating moiety may be replaced by a chelator of the general formula I, as described above.

(v) Linear  $\alpha$ -MSH Receptor Targeting Agents

Naturally occurring  $\alpha$ -MSH has the sequence:

Ac-SYSMEHFRWGKPV-NH<sub>2</sub>.

It had previously been shown that the cyclic peptide NleDHF<sub>d</sub>RWK-NH<sub>2</sub> (where Nle is norleucine and F<sub>d</sub> indicates D-Phe) has a high affinity for the  $\alpha$ -MSH receptor and is known to be relatively stable *in-vivo*. See Al-Obeidi et al. *J. Amer. Chem. Soc.* 111:3413 (1989); Haskell-Luevano et al. *J. Med. Chem.* 39:432 (1996). The underlined portion indicates those residues within the cyclized portion of the peptide, and also the termini of the cyclic structure, i.e. the peptide is cyclized by an amide bond from the side chains of aspartic acid and lysine.

Linear chelating derivatives based upon the structures of these known  $\alpha$ -MSH receptor binding peptides include those with a chelating derivative attached to the N-terminus of the peptide, either directly or via a spacer group, such as  $\gamma$ -amino butyric acid ( $\gamma$ -Abu). Specific linear chelating derivatives with this general structure include, but are not limited to:

MaGC $\gamma$ AbuSYSNleDHF<sub>d</sub>RWK-NH<sub>2</sub>, and

MaGC $\gamma$ AbuSYSNleDHF<sub>d</sub>R<sub>n</sub>WK-NH<sub>2</sub>

where  $\gamma$ -Abu is  $\gamma$ -aminobutyric acid and R<sub>n</sub> is a nitrated arginine residue.

In each of the compounds described above, the chelating moiety may be replaced by a chelator of the general formula I, as described above.

## B. Design and Synthesis of Cyclic Peptides Incorporating Chelating Amino Acid Derivatives

### (i) In General

5 The process of preparing a cyclic metal-  
chelator/peptide complex is analogous to that described  
above for linear peptides, except that at some point  
during or subsequent to synthesis of the peptide chain  
cyclization is carried out. The cyclization can be  
10 between any two functional groups on the peptide such as  
the peptide termini or amino acid side chains. The  
cyclization can be achieved by disulfide or sulfide  
formation, or preferably by lactam formation. Site-  
selective cyclization requires selective deprotection of  
two functional groups on the peptide. For lactam  
15 formation this requires using an amino and a carboxyl  
protecting group that can be deprotected in the presence  
of other amino and carboxyl protecting groups. This task  
is made more difficult when the peptide synthesis also  
requires that selective deprotection be achieved between  
20 these other protecting groups. Accordingly, such a  
sophisticated protecting group strategy has heretofore  
proved difficult to achieve in practice.

The methods of the present invention allow both  
cyclization and coupling of the chelator moiety to the  
25 peptide to be achieved at any point during peptide  
synthesis. Use of appropriate protecting groups allows  
synthesis of the peptide, assembly of the ligand and  
cyclization of the peptide to be achieved in any order  
that is desired. This approach is more efficient than  
30 either solid-phase methods which cyclize the peptide off  
the resin or methods that attach ligands in solution  
following synthesis of the cyclic peptide.

The methods of the present invention may be used in  
solution phase, but preferably are carried out using an  
35 automated solid-phase peptide synthesizer. Using a  
multi-well automated synthesizer allows a large number of  
peptides, differing in the point of attachment of the

chelator moiety or in the site of cyclization, to be prepared simultaneously. These so-called "combinatorial libraries," wherein the ligand containing peptides are deprotected while still attached to the solid support, can be reacted with the appropriate metal to form complexes and then screened in an appropriate bioactivity assay to select the compound having the optimally desired characteristics of receptor binding and stability.

Combinatorial synthesis can be carried out in "split" syntheses or by "parallel" syntheses. In split synthesis, synthetic peptide intermediates bound to beads are subdivided into different groups for addition of the next amino acid in each successive step. After each step the beads are divided into different groups for the next reaction. In parallel synthesis, different compounds are synthesized in different reactions vessels, such as the wells of a peptide synthesizer. Split synthesis provides small quantities of large numbers of compounds, whereas parallel synthesis provides larger quantities of a smaller number of compounds.

Combinatorial synthesis also requires that each individual compound be labeled in some way in order that it might be identified in the screening step. Various means of labeling compounds for this purpose are known in the art. For example, inert halogenated aromatic compounds are used as labels that can be identified by gas chromatography. See Borman, *Chem. Eng. News* 74:29 (1996) which is hereby incorporated herein in its entirety.

In a preferred embodiment of the invention cyclization is achieved by lactam formation. Most preferably the amino function is protected using an aloc group, and the carboxyl function is protected as an allyl ester. This allows simultaneous deprotection of the amino and carboxy functions using  $\text{Pd}(\text{PPh}_3)_4$  in the presence of a nucleophile for the allyl group. The nucleophile typically used is tri-n-butyl tin hydride ( ${}^n\text{Bu}_3\text{SnH}$ ).

Prior to the present invention it was known that amines would react with allyl ions under Pd<sup>0</sup> catalysis. See, for example, Roos et al., *J. Org. Chem.* 60:1733 (1995) and Heck, *PALLADIUM REAGENTS IN ORGANIC SYNTHESSES*, Academic Press, 1995, pp. 122-131. The present inventors found that this caused a problem for simultaneous deprotection of allyl-protected amino and carboxyl functions because of the side reaction wherein the newly deprotected amino function was alkylated with the allyl group. It was found, however, that addition of piperidine as an allyl scavenger during the Pd-catalyzed aloc cleavage reaction inhibited this unwanted side-reaction. This allowed deprotection of, for example, aspartic acid and lysine side chains selectively and simultaneously while greatly reducing formation of the undesired N<sup>ε</sup>-allyl lysine. Those skilled in the art will recognize that other primary or secondary amines will also be suitable allyl scavengers.

This method is useful and advantageous because it is compatible with Fmoc based peptide synthesis. It allows preparation of cyclic peptides on HMP and PAM resins where both the Boc or Fmoc side chain protection can be used in addition to Aloc side chain protection. This technique furthermore allows synthesis of cyclic peptides containing a metal-binding ligand attached to the side chain of an amino acid at any point in a peptide chain. Thus three orthogonal nitrogen protecting groups are used: one for building the peptide chain, such as Fmoc or Boc; a second for attaching a metal-binding ligand to a side chain of a bisaminoacid such as 4-methyltrityl(mtt) or 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (Dde); and a third, such as Aloc, for achieving side-chain to side-chain cyclization. Other protecting groups, such as Boc, Cbz, <sup>t</sup>Bu and benzyl groups can be used for protection of other side-chain amino and carboxy functions that are not deprotected until the peptide synthesis is finished. Combinations of these protecting groups allow the use of Rink, Wang, Merrifield, PAM and

HMP-type resins for solid-phase peptide synthesis. Cleavage of the peptides from the resin can be accomplished with trifluoroacetic acid (for Fmoc-based syntheses) or HF or trimethylsilyl trifluoromethanesulfonate (for Boc-based syntheses).

The cyclic peptides of the invention are from 4 to 100 residues long, and have up to 5 metal chelating groups. The peptides can contain cyclized regions that are between 2 and 60 amino acids in length, and can contain more than one cyclic portion.

Cyclization is preferably between amino and carboxy amino acid side chains to form lactam bridges, but may also be between a side chain amine and the carboxy terminus to form a lactam bridge, between a side chain acid and the N-terminal amine to form lactam, between thiols to form disulfide bridges, between hydrazines and esters to form hydrazides, between hydrazines and aldehydes to form hydrazones, between a thiol and a suitable leaving group to form a sulfide, or between a hydroxyl group and another suitable leaving group to form an ether. When more than one cyclic region is present in the compound, the bridges in the cyclic regions may be of the same or different types.

When a cyclic disulfide is to be formed, the peptide of interest is preferably synthesized using Acm protection on thiols and aloc protection on amino side chains. The aloc is cleaved and the chelating ligand is coupled to the peptide. The Acm group is then cleaved and the disulfide cyclized using thallium trifluoroacetate. Alternatively, the thiols can be protected using S-trityl groups, and the cyclization can be carried out in solution after cleavage from the resin.

Preparation of a cyclic sulfide may be achieved by, for example, cyclization of a thiol onto an  $\alpha$ -haloamido function present on an amine side chain. Thus, for example, the peptide may be synthesized with Fmoc protection on the N-terminus and S-trityl protection on

the thiol. An aloc-protected lysine side chain is then deprotected and the chelator is coupled to the lysine as described above. The Fmoc is cleaved and reacted with chloroacetyl chloride or an equivalent reagent. If an acid stable resin such as the photocleavable BromoWang resin, Wang, *J. Org. Chem.* 41:3258 (1976), is used the thiol protecting group is removed and the peptide is cyclized on the resin.

Cyclic sulfides between side chain residues are prepared by using a suitable protecting group on the N-terminus of the peptide that allows selective deprotection at two differentially protected amino side chains. For example, the N-terminus can be protected as an acetyl or Boc group, and the side chains can be protected as Fmoc and aloc groups. Following peptide synthesis, one amino acid side chain (for example, Fmoc) is selectively deprotected and coupled with the chelate moiety as described above. Another amino side chain (for example aloc or Dde) is then deprotected and coupled to a sulfide electrophile such as haloacetyl or maleimide. The protecting group on the sulfur of interest is cleaved and cyclization is carried out on the resin using a base catalyst. Alternatively, the peptide can be cleaved and the cyclization can be carried out in solution.




As set forth above, a wide variety of cyclic peptides may be prepared using the methods of the present invention. Additional methods of preparing cyclic metal chelating peptides using the methods of the claimed invention will be apparent to the skilled artisan. Specific applications using these methods are set forth below to further exemplify the invention, but it will be appreciated that these examples are merely illustrative and are not meant to limit the scope of application of the invention.



(ii) Cyclic  $\alpha$ -MSH Receptor Targeting Agents

Naturally occurring  $\alpha$ -MSH has the sequence Ac-SYSMEHFRWGKPV-NH<sub>2</sub>. It had previously been shown that the cyclic peptide NleDHF<sub>4</sub>RWK-NH<sub>2</sub> (where Nle is norleucine and F<sub>4</sub> indicates D-Phe) has a high affinity for the  $\alpha$ -MSH receptor and is known to be relatively stable *in-vivo*. See Al-Obeidi et al. *J. Amer. Chem. Soc.* 111:3413 (1989); Haskell-Luevano et al. *J. Med. Chem.* 39:432 (1996). The underlined portion indicates those residues within the cyclized portion of the peptide, and also the termini of the cyclic structure, *i.e.* the peptide is cyclized by an amide bond from the side chains of aspartic acid and lysine. This cyclic structure is used as a basis for constructing labeled peptides according to the present invention.

Cyclic chelating derivatives based upon the structure of the known  $\alpha$ -MSH receptor binding ligand include those with a chelating derivative attached to the N-terminus of the peptide, either directly or via a spacer group, such as  $\gamma$ -amino butyric acid ( $\gamma$ -Abu). Specific chelating derivatives of this general structure include, but are not limited to:



where

Ma is mercaptoacetic acid,

$\gamma$ Abu is  $\gamma$ -aminobutyric acid,

PtscG is 2-(4-phenyl-3-thiosemicarbazidyl)acetic acid, and

DTPA is diethylenetriaminepentaacetic acid.



In each of the compounds described above, the chelating moiety may be replaced by a chelator of the general formula I, as described above.

(iii) Cyclic VIP Receptor Targeting Agents

Naturally occurring VIP has the sequence:



Native VIP is thought to form a helical structure in solution. See Musso et al. *Biochemistry* 27:8174 (1988). The putative helix structure can be stabilized by intramolecular cyclization via the side chains of residues placed in spatial proximity by the helical structure. Examples include:




(where Nle is norleucine). See O'Donnell et al. *J. Pharm. Exp. Ther.* 270:1282; US Patent 4,822,890; Bolin, Eur Pat Appl 0 536 741 A2. The underlined portion indicates the residues within the cyclized portion of the peptide, and also the termini of the cyclized portion, i.e. the peptide is cyclized via the formation of an amide bond between the side chains of the aspartic acid and the lysine. These cyclic structures are used as a basis for constructing labeled peptides according to the present invention.

Cyclic chelating derivatives based on these structures include, but are not limited to, those with a metal binding moiety attached, either directly or via a spacer group, to the pharmacophore via the side chain amine of a lysine or other bis-amino acid residue. Specific chelating derivatives of this general structure include, but are not limited to:



(where PtscG = 2-(4-phenyl-3-thiosemicarbazidyl)acetic acid); and



In each of the compounds described above, the chelating moiety may be replaced by a chelator of the general formula I, as described above.

The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention.

5

### Examples

#### **Example 1: Synthesis of N<sup>α</sup>Alloc-N<sup>ε</sup>-Fmoc-L-Lysine**

10 N<sup>ε</sup>-Fmoc-L-Lysine (10.00 g, 27.1 mmol, 100 mol%, Bachem Biosciences, Inc.) was suspended in dioxane (100 ml) and Na<sub>2</sub>CO<sub>3</sub> (1M, 33 ml) to form a milky suspension. Allyl chloroformate (3.2 ml, 30.2 mmol, 111 mol%) was added to dioxane (10 ml) and this solution was added dropwise to the suspension of N<sup>ε</sup>-Fmoc-L-Lysine over 10 min. Sodium carbonate, (1M, 20 ml) was added in two portions and an additional quantity of allyl chloroformate (0.3 ml) was added. The reaction was stirred at room temperature for 16 hours. The volatile solvents were removed under reduced pressure and the residue was washed with diethyl ether (50 ml). The residual liquid was then acidified with HCl (1M) and extracted with ethyl acetate (2x150 ml). The organic layers were combined, washed with saturated NaCl (50 ml), dried over Na<sub>2</sub>SO<sub>4</sub>, evaporated under reduced pressure to obtain a crude oily product (16g). The crude product was dissolved in ether (100 ml) and a white solid formed and was removed by filtration. The solvent from the filtrate was removed under reduced pressure to afford a viscous pale yellow oil (8.34 g, 68% yield) which eventually formed a glassy solid.

#### **Example 2: Synthesis of 2-(triphenylmethylmercapto) acetyl hydrazide**

30 2-(triphenylmethylmercapto) acetic acid (20.35 g, 60.9 mmol, 100 mol%) was dissolved in anhydrous THF (150 ml) and cooled in an ice water bath. t-Butylcarbazate (8.61 g, 65.1 mmol, 107 mol%) was added to the reaction solution followed by diisopropylcarbodiimide (10.0 ml,

35

63.9 mmol, 105 mol%). The reaction was allowed to warm slowly to room temperature and stirred for 28 hours. The reaction mixture was filtered to remove the white precipitate that had formed and the filtrate was concentrated to a white foam by removal of the solvent under reduced pressure. This material was dissolved in chloroform (75 ml). Then acetic acid (75 ml) was added followed by the addition of borontrifluoride etherate (10.0 ml, 81 mmol, 134 mol%). The reaction was stirred at room temperature for 6 hours and then quenched by pouring the reaction mixture into water (200 ml) containing sodium acetate (30 g). This mixture was extracted with chloroform (2x100 ml). The organic layers were combined, washed with saturated NaCl solution (150 ml), dried over Na<sub>2</sub>SO<sub>4</sub> and filtered. The solvent was removed under reduced pressure to obtain a pale gold oil which solidified on standing. The solid was suspended in 1:1 diethylether/hexanes (200 ml) and collected by filtration. The solid was washed with an additional quantity of 1:1 diethylether/hexanes (100 ml) and dried to afford the desired product (15.44 g, 73% yield) having ESMS MH<sup>+</sup> calculated 349, observed 349.

**Example 3: Synthesis of N<sup>δ</sup>-[2-(triphenylmethylthio)acetyl]azaglycine**

Glyoxylic acid monohydrate (0.59 g, 6.41 mmol, 110 mol%) was dissolved in methanol (20 ml) and 2-(triphenylmethylmercapto)acetyl hydrazide (2.03 g, 5.82 mmol, 100 mol%) was added. Dioxane (20 ml) was added to the cloudy reaction mixture and the reaction was stirred at room temperature for 18 hours. Sodium borohydride (1.76 g) was added to the reaction mixture and after 30 minutes, another quantity of sodium borohydride (0.60 g) was added. The reaction was stirred for 3 hours at room temperature, then quenched by pouring the reaction mixture into HCl (1M, 60 ml). The mixture was extracted with ethyl acetate (2x50 ml). The organic layers were combined, washed with saturated NaCl solution (40 ml),

dried over  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated under reduced pressure on the rotary evaporator to afford a solid (2.5 g) having ESMS  $\text{MH}^+$  calculated 407, found 407.

**Example 4: Synthesis of  $\text{N}^\alpha$ -Boc- $\text{N}^\beta$ -[2-(triphenylmethylthio)acetyl] azaglycine**

$\text{N}^\beta$ -[2-(triphenylmethylthio)acetyl]azaglycine (2.39 g, 5.89 mmol, 100 mol%) was dissolved in dioxane (50 ml). Di-*t*-butyl dicarbonate  $(\text{BOC})_2\text{O}$ , (2.07 g, 9.48 mmol, 161 mol%) was added to the reaction solution followed by the addition of  $\text{Na}_2\text{CO}_3$  (1M, 15 ml). This mixture was stirred at room temperature for 15 minutes, then additional quantities of  $\text{Na}_2\text{CO}_3$  (1M, 10 ml) and  $(\text{BOC})_2\text{O}$  (1.41 g) were added. The solution was stirred at room temperature for 18 hours then reacted with NaOH (6M, 3 ml) and  $(\text{BOC})_2\text{O}$  (1.4 g) for 1 hour. The crude reaction mixture was then acidified to pH 3 with citric acid (1M) and extracted with ethyl acetate (200 ml). The organic layer was washed with saturated sodium chloride solution (60 ml), dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated under reduced pressure to obtain the crude product. The crude product was dissolved in ether and diluted to obtain a 1:1 mixture with hexanes causing a white precipitate to form. The white solid was collected by filtration to obtain the desired product (1.48 g, 50% yield) having ESMS  $\text{MH}^+$  calculated 507, found 507.

**Example 5: Synthesis of 2-(4-Phenyl-3-thiosemicarbazidyl)acetic acid**

4-Phenyl-3-thiosemicarbazide (6.02 g, 36 mmol, 100 mol%) was suspended in methanol (40 ml). Glyoxylic acid monohydrate (3.32 g, 36.1 mmol, 100 mol%) was added and the reaction was stirred at room temperature for 2 hours. Sodium borohydride (1.50 g) was added carefully, and the reaction mixture bubbled very vigorously. The reaction mixture was stirred at room temperature for 1 hour, then  $\text{NaBH}_4$  (0.66 g) was added, followed by the addition of glacial acetic acid (6 ml). After 15

minutes,  $\text{NaBH}_4$  (1.08 g) was added, and the reaction was stirred at room temperature for 15 hours. An additional quantity of  $\text{NaBH}_4$  (1.66 g) was then added and the reaction was stirred at room temperature for 3 hours before it was quenched with  $\text{HCl}$  (1M, 200 ml). The mixture was then extracted with ethyl acetate (2x150 ml). The organic layers were combined, washed with saturated  $\text{NaCl}$  solution (100 ml), dried over  $\text{Na}_2\text{SO}_4$ , filtered, and the solvent removed under reduced pressure to afford a yellow solid (9.03 g) having ESMS Negative ion mode  $\text{M-H}^+$  Calculated 224 Found 224.

**Example 6: Synthesis of  $\text{N}^\beta$ -Boc-2-(4-Phenyl-3-thiosemicarbazidyl)acetic acid**

2-(4-Phenyl-3-thiosemicarbazidyl)acetic acid (8.93 g, 37.9 mmol, 100mol%) and  $(\text{BOC})_2\text{O}$  (9.10 g) were dissolved in dioxane (100 ml). Sodium carbonate (1M, 50 ml) and water (50 ml) were added and the mixture was stirred at room temperature for 5 hours. Sodium hydroxide (1M, 40 ml) and an additional quantity of  $(\text{BOC})_2\text{O}$  (6.21 g) were added and the reaction was stirred overnight at room temperature. The reaction was quenched with citric acid (1M) and extracted with ethyl acetate (2x100 ml). The organic layers were combined, washed with saturated  $\text{NaCl}$  (50 ml), dried over  $\text{Na}_2\text{SO}_4$ , and filtered. The filtrate was concentrated under reduced pressure to afford a gummy solid (19 g). The crude solid was suspended in ether and a white solid was collected by filtration. The solid was washed with ether (100 ml) to obtain the desired product (3.17 g) having ESMS  $\text{MH}^+$  calculated 326, found 326.

**Example 7: Synthesis of  $\text{N}^\alpha$ -(triphenylmethylsulfenyl)- $\text{N}^\beta$ -(Boc)azaglycine**

$\beta$ -Butylcarbazate was condensed with glyoxylic acid monohydrate in methanol. This crude hydrazone was then reduced by catalytic hydrogenation over 10%  $\text{Pd/C}$ . This product was then mixed with dioxane and base and a

dioxane solution of triphenylmethanesulfenylchloride was added dropwise. The desired N<sup>α</sup>-(triphenylmethylsulfenyl)-N<sup>β</sup>-(Boc)azaglycine (25 g) was obtained on work-up.

**Example 8: Solid Phase Peptide Synthesis of Peptides Using Alloc and Fmoc Protecting Groups**

Solid phase peptide synthesis was carried out on a 0.050 mmol scale using an Advanced ChemTech model 348 peptide synthesizer modified to operate under nitrogen pressure in the same manner as the model 396. The allyloxycarbonyl (alloc) and 9-fluorenylmethyloxycarbonyl (Fmoc) groups were employed for nitrogen protection and diisopropylcarbodiimide (DIC)/ hydroxybenzotriazole (HOBT) were used to activate the carboxyl groups for coupling. A variety of resins were used such as Rink, Pal, and TentaGel S RAM for C-terminal amides and Wang, 2-chlorotrityl, or TentaGel S PHB for C-terminal acids.

To allow either introduction of the metal binding chelate moiety and/or to allow cyclization via selectively deprotected amino acid side chains a differentially protected bis-amino acid was used for the peptide synthesis. The differentially protected bis-amino acid derivatives chosen were α-Aloc-Lys(ε-Fmoc)OH and α-Fmoc-Lys(ε-Aloc)OH. The α-Aloc-Lys(ε-Fmoc)OH derivative allowed the ligand pieces to be introduced on the side chain using a routine Fmoc procedure.

The alloc groups were cleaved on the machine in the manual mode by washing the resin bound peptide with dichloromethane (3 x 2 ml portions) and then mixing the resin with a solution (2 ml) containing tetrakis(triphenylphosphine) palladium [0] (10 mg), and acetic acid (0.1 ml). Tributyltinhydride (0.3 ml) was then added and the mixture was vortexed for one hour. The reaction cell was then emptied, the resin was washed with dichloromethane (3 x 2 ml) and standard Fmoc synthesis was then resumed. The peptides were cleaved

from the resin with a solution of trifluoroacetic acid (TFA), anisole and ethane dithiol for 1 to 3 hours in the ratio 23:3:1. The crude cleavage mixture was then poured into ether to precipitate the crude peptide which was then purified by reverse phase HPLC using a Waters Delta Pak, Prep Pak C-18 cartridge system eluted with an appropriate gradient of TFA (0.1%) in water and/or TFA (0.1%) in acetonitrile (90%) and water (10%). The fractions containing the desired purified peptides were collected and the volatile solvents were removed under reduced pressure to obtain the aqueous solutions of the peptides which were then lyophilized. Samples of the lyophilized products were then sent for electrospray (ESMS) or fast atom bombardment (FABMS) to confirm that the observed mass of the products matched the calculated mass of the desired peptide.



The table below shows some of the peptide sequences synthesized by the methods described above.

	Peptide	HPLC <sup>a</sup>	MW <sup>b</sup>
5	<GHWSYGLRPG-NH <sub>2</sub>	6.1	1183
	<GHYSLEWKPG-NH <sub>2</sub>	6.2	1227
	HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH <sub>2</sub>	6.7	3326
	MaGCγAbuHSDAVFTDNYTRLRKQMAVKKYLNSILN-NH <sub>2</sub>	7.3	3645
	MaGCγAbuVFTDNYTRLRKQMAVKKYLNSILN-NH <sub>2</sub>	7.5	3235
10	MaGCγAbuNleDHF <sub>d</sub> RWK-NH <sub>2</sub> <sup>c</sup>	7.0	1302
	<GHWSYK(MaGC)LRPG-NH <sub>2</sub>	6.3	1488
	<GHYSLK(MaGC)WKPG-NH <sub>2</sub>	6.3	1460
	<GHWSYK(Ma-azaGC)LRPG-NH <sub>2</sub>	6.1	1503
	<GHYSLK(PtscGC)WKPG-NH <sub>2</sub>	6.9	1536
15	AcNal <sub>d</sub> Cpa <sub>d</sub> W <sub>d</sub> SRK <sub>d</sub> (MaGC)LRPA <sub>d</sub> -NH <sub>2</sub>	8.2	1668
	<GHYSYLK(PtscGDap)WKPG-NH <sub>2</sub>	6.6	1519
	<GHYSLK(azaGGC)WKPG-NH <sub>2</sub>	6.5	1474
	Nal <sub>d</sub> Cpa <sub>d</sub> W <sub>d</sub> SRK <sub>d</sub> (PtscGC)WKPG-NH <sub>2</sub>	8.1	1701
	<GHWSYK <sub>d</sub> (MaGC)LRPG-NH <sub>2</sub>	6.3	1488
20	AcNal <sub>d</sub> Cpa <sub>d</sub> W <sub>d</sub> SRK <sub>d</sub> (AzaGFC)LRPA <sub>d</sub> -NH <sub>2</sub>		
	AcNal <sub>d</sub> Cpa <sub>d</sub> W <sub>d</sub> SRK <sub>d</sub> (MaFC)LRPA <sub>d</sub> -NH <sub>2</sub>		
	AcNal <sub>d</sub> Cpa <sub>d</sub> W <sub>d</sub> SRK <sub>d</sub> (PtscGC)LRPA <sub>d</sub> -NH <sub>2</sub>		
	<GHWSYK(iDGDap)LRPG-NH <sub>2</sub>		
	<GHWSYK(iECG)LRPG-NH <sub>2</sub>		
25			

<sup>a</sup> HPLC Method [retention time in minutes] Solvent A is 0.1% trifluoroacetic acid in water, Solvent B is 0.1% trifluoroacetic acid in 90:10 acetonitrile/water. Solvent flow rate is 3 ml/min for 10 min, then 5 ml/min for 5 min. Gradient is 0 to 100% B over 10 min then 100%B for 5 min

<sup>b</sup> Electrospray mass spectrum values (MH<sup>+</sup>)

<sup>c</sup> The underlined sequence is cyclized as the cyclic amide connecting the side chain functional groups

Abbreviations used in Table:

<G:	pyroglutamic acid
PtscG:	2-(4-phenyl-3-thiosemicarbazidyl)acetic acid or $\text{PhNHCSNHNHCH}_2\text{CO}_2\text{H}$
Ma:	mercaptoacetic acid
5 azaG:	azaglycine or $\text{H}_2\text{NNHCH}_2\text{CO}_2\text{H}$
Dap:	2,3-diaminopropionic acid
$\gamma$ Abu:	$\gamma$ -aminobutyric acid
Nal:	2-naphthylalanine
Cpa:	4-chlorophenylalanine
10 K <sub>d</sub> :	the subscript d denotes that the D isomer was used
K(MaGC):	the parentheses denote that enclosed amino acids are attached to the $\epsilon$ amine of lysine and the first amino acid attached is C followed by G and ending in Ma
iD:	isoaspartic acid
iE:	isoglutamic acid

15 Other peptides synthesized by these methods include:

Sequence	MH+	HPLC RT
AcK(TscGC) <u>F<sub>d</sub>CFW<sub>d</sub>KTCT</u> -OH	1436	7.7
AcK(TscGC) <u>DF<sub>d</sub>CFW<sub>d</sub>KTCT</u> -OH	1552	7.4
TscGCDF <sub>d</sub> <u>CFW<sub>d</sub>KTCT</u> -OH	1381	7.7
20 AcK(TscGC) <u>F<sub>d</sub>CFW<sub>d</sub>KTCT</u> -ol	1422	7.6
AcK(MtscGC) <u>F<sub>d</sub>CFW<sub>d</sub>KTCT</u> -ol	1436	7.8
AcK(TscGC) <u>DF<sub>d</sub>CFW<sub>d</sub>KTCT</u> -ol	1537	7.4
AcK(MaGG) <u>F<sub>d</sub>CFW<sub>d</sub>KTCT</u> -ol	1378	7.4
K(TscGC) <u>DF<sub>d</sub>CFW<sub>d</sub>KTCT</u> -NH <sub>2</sub>	1508	7.1
25 K(TscGC) <u>KKF<sub>d</sub>CFW<sub>d</sub>KTCT</u> -ol	1651	7.2
K(TscGC) <u>KDF<sub>d</sub>CFW<sub>d</sub>KTCT</u> -OH	1637	7.3
K(TscGC) <u>DF<sub>d</sub>CFW<sub>d</sub>KTCT</u> -ol	1495	7.2
K(TscGC) <u>DSF<sub>d</sub>CFW<sub>d</sub>KTCT</u> -OH	1596	7.4
K(TscGC) <u>DF<sub>d</sub>CFW<sub>d</sub>KTCT</u> -OH	1508	7.2
30 K(TscGC) <u>DF<sub>d</sub>CFW<sub>d</sub>KTCD</u> -NH <sub>2</sub>	1521	7.1
K(TscGC) <u>KDF<sub>d</sub>CFW<sub>d</sub>KTCT</u> -NHNH <sub>2</sub>	1651	7.2
AcK(TscGC) <u>F<sub>d</sub>CFW<sub>d</sub>KTCT</u> -NHNH <sub>2</sub>	1450	7.4
K(AGC) <u>F<sub>d</sub>CFW<sub>d</sub>KTCT</u> -ol	1379	6.8
AcK(TscGC) <u>DF<sub>d</sub>CFW<sub>d</sub>KTCT</u> -ol	1537	7.4
35 <u>F<sub>d</sub>CFW<sub>d</sub>KTCT</u> K(TscGC)-NH <sub>2</sub>	1393	6.8

The underlined portion of the sequence is cyclic.

TscG is 3-thiosemicarbazonylglyoxyl, i.e.  $\text{H}_2\text{NCSNHNHCHCO-}$

MtscG is 4-methyl-3-thiosemicarbazonylglyoxyl, i.e.  $\text{CH}_3\text{NHCSNHNHCHCO-}$

Ma is mercaptoacetyl:  $\text{HSCH}_2\text{CO-}$

Groups listed within parentheses are attached to the side chain of the amino acid to the left of the parentheses

**Example 9: Preparation of a cyclic MSH analogue containing a chelating moiety**

The method of synthesizing cyclic peptides was demonstrated by preparing the cyclic  $\alpha$ -melanocyte stimulating hormone ( $\alpha$ MSH) analogue MaGC $\gamma$ -AbuNleDHF<sub>4</sub>RWK-NH<sub>2</sub>, where the underlining indicates that the peptide sequence is cyclized as a lactam through the aspartic acid and lysine side chains. The residues to be used for cyclization were side-chain protected as the aloc group (for lysine) and as the allyl ester (for aspartate). The peptide was assembled using Fmoc chemistry as described above, on a polystyrene-based Rink amide resin.

Allyl and aloc deprotection was first carried out using Pd(PPh<sub>3</sub>)<sub>4</sub>, acetic acid, and Bu<sub>3</sub>SnH in the absence of piperidine as an allyl scavenger. After cleavage of the side chain protecting groups, the resin was washed and the partially protected peptide was cyclized using the method described by Felix et al., *Int. J. Peptide Protein Res.* 32:441 (1988). The peptide was then cleaved from the resin and purified to isolate the N-allyl substituted cyclic amide as the only clean peptide from the product mixture.

The aloc cleavage reaction was then modified by the addition of piperidine as an allyl scavenger.

When the aloc and allyl groups were cleaved using a mixture containing 0.5 ml glacial acetic acid, 10 ml dichloromethane, 0.0563 g tetrakis(triphenylphosphine)palladium (0), plus 1.0 ml piperidine as an allyl scavenger. Each well on the peptide synthesizer contained 0.05 mmol of peptide on Rink resin, and was treated with 0.3 ml/well tributyltin hydride at room temperature for 1 hr with vortex mixing. The resin was washed with: 2x2 ml/well dichloromethane, 2x1 ml/well methanol, 2x1 ml/well diisopropylethyl amine, and 3x1 ml/well NMP after the cleavage of the side chain protecting groups. The peptide side chains were then coupled by the method of Felix *supra* (15 hr, using BOP and DIEA). The peptide was cleaved and purified as

described above to afford a pure peptide with the desired ESMS MH<sup>+</sup> of 1302. The N-allylated side product was observed in only trace amounts.

**Example 10: Radiolabeling with <sup>99m</sup>Tc**

5 A Glucoscan (DuPont) vial was reconstituted with 2.18 mCi of NaTcO<sub>4</sub> in 1 ml saline to form the <sup>99m</sup>Tc-glucaptate complex. <GHWSYK(MaGC)LRPG amide (IMP3) was prepared as above. <sup>99m</sup>Tc-IMP3 was prepared by mixing 360 μl (874 uCi) of <sup>99m</sup>Tc-glucaptate with 640 μl of peptide in saline. The  
10 initially formed precipitate disappeared upon heating for 15 min at 75°C. An instant TLC (ITLC) strip developed in H<sub>2</sub>O:EtOH:NH<sub>4</sub>OH mixture (5:2:1) showed 6.2% of the activity at the origin as colloids. HPLC showed 100% of the activity bound to the peptide with a RT of 6.95 min, whereas the unlabeled peptide eluted at 6.4 min under the  
15 same HPLC conditions (reversed phase C-18 column, gradient of 0-100% B in 10 min at a flow rate of 3 ml/min, where A is 0.1% TFA in H<sub>2</sub>O and B is 90% CH<sub>3</sub>CN, 0.1% TFA). Recovery from the HPLC column was 85% of the  
20 injected activity.

IMP3 was formulated and lyophilized for <sup>99m</sup>Tc labeling in the amounts shown below:

	IMP3 (μg)	Sn (μg)	αDG/Sn
25	1. 250	23	14
	2. 100	23	14
	3. 250	15	14

where αDG is α-D-glucoheptonate. The lyophilized vials were reconstituted with ~900 μuCi of NaTcO<sub>4</sub> in saline. Cloudiness was observed in all the vials. The vials were  
30 heated for 15 min at 75°C, but turbidity persisted. ITLC analysis for colloids showed 14, 21 and 9% colloids at the origin for vials 1, 2, and 3, respectively.

In order to prevent the precipitation during <sup>99m</sup>Tc labeling, α-D-glucoheptonate (αDG) and tartrate ratios to  
35 Sn(II) were varied in the lyophilized vials. The

5 following vials were formulated and lyophilized (250  $\mu$ g of IMP3 with 25  $\mu$ g Sn(II)) with tartrate and  $\alpha$ DG ratios as shown below. The vials were reconstituted with ~500  $\mu$ Ci of NaTcO<sub>4</sub> in 1 ml saline. Observations are indicated in the observation column. ITLC strips were developed after 15 min at room temperature following heating at 75°C for 15 min.

	tartrate/Sn	pH	Observation	colloid, RTcolloid, 75°C
10	1. 50	5.3	ppt	
	2. 100	5.3	ppt	
	3. 500	5.3	ppt clears upon mixing	17 %2.4%
	$\alpha$ DG/Sn	pH	Observation	colloid, RTcolloid, 75°C
15	4. 25	5.3	ppt	
	5. 50	5.3	ppt	
	6. 100	5.3	turbid	
	7. 500	5.3	slight turbidity	25 %3.5%
	8. 1000	5.3	clear	3.3%3.1%

20 The protocol above was repeated for vials 3, 7 and 8 and colloids were determined to be 5.3, 3.8, and 4.6%, respectively after heating 15 min at 75°C. A single broad peak was observed on a reversed HPLC column at a RT of 7 min.

25 Solubility of peptides that are poorly soluble in saline alone is increased by the addition of a solubilizing agent such as ethanol or 2-hydroxypropyl- $\beta$ -cyclodextrin.

Results from labeling other peptides with technetium-99 are shown in the table below:

Peptide	HPLC retention time <sup>a</sup>	HPLC retention time <sup>b</sup>
MaGC $\gamma$ AbuHSDAVFTDNYTRLRKQ MAVKKYLSILN-NH <sub>2</sub>	7.62 (99%)	7.65
MaGC $\gamma$ AbuVFTDNYTRLRKQMAV KKYLSILN-NH <sub>2</sub>	7.8-9.7 <sup>e</sup>	8.19 <sup>c</sup> (99%)
<GHWSYK(MaGC)LRPG.amide	6.59 (95%)	6.90 <sup>c</sup> (92%)
<GHYSLK(MaGC)WKPG.amide	NA	7.07 (100%)
<GHWSYK(Ma-azaGC)LRPG.amide	6.82 (100%)	7.02 <sup>c</sup> (99%)
<GHYSLK(Ptsc-GC)WKPG amide	7.60 (100%)	7.67 <sup>d</sup> (100%)
AcNa <sub>d</sub> Cpa <sub>d</sub> W <sub>d</sub> SRK <sub>d</sub> (MaGC)LRPA <sub>d</sub> - NH <sub>2</sub>	8.50 (27%) 9.00 (68%)	
<GHWSYK <sub>d</sub> (MaGC)LRPG-NH <sub>2</sub>	6.83 (95%)	7.07 <sup>c</sup> (95%)
<GHYSYK(PtscGDap)WKPG-NH <sub>2</sub>	7.08 (96%)	6-8 <sup>c</sup> (90%)
<GHYSLK(azaGGC)WKPG-NH <sub>2</sub>	6.60 (100%)	6.47 <sup>c</sup> (99%)
Na <sub>d</sub> Cpa <sub>d</sub> W <sub>d</sub> SRK <sub>d</sub> (PtscGC)WKPG-NH <sub>2</sub>	8.43 (97%)	

Abbreviations used in the table are the same as in Example 8 *supra*. A change in HPLC retention time of the complex formed by labeling at room temperature and that formed by heating indicates a change in the binding of the metal.

<sup>a</sup> room temperature reaction 15 min [retention time in minutes]

<sup>b</sup> after heating in boiling water 15 min

<sup>c</sup> significant change in peak shape and retention after heating

<sup>d</sup> no change in peak shape and retention time difference is not significant

<sup>e</sup> many peaks

In an alternative labeling method, dilute solutions (30  $\mu$ g/mL) of the peptide were formulated into labeling kits prior to addition of pertechnetate. The final

5 solution contained the peptide, 10% hydroxypropyl-  
βcyclodextrin (HPCD), 200 mM glucoheptonate 21 mM acetate  
buffer at pH 5.3, 2 mg of ascorbic acid and 100 μg of  
stannous chloride in 1.5 mL total volume. In other  
formulations, two equivalents of stannous ion relative to  
the peptide were added, in a buffer containing 15 %  
HPCD, 200 mM glucoheptonate, and 21 mM acetate buffer at  
pH 5.6.

**Example 11: Radiolabeling of IMP-3 <sup>188</sup>Re**

10 IMP3, (<GHWSYK(MaGC)LRPG amide) was synthesized as  
above. IMP 3 has a retention time of 6.4 min on a  
reversed phase C-18 column using a gradient of 0-100% B  
in 10 min at a flow rate of 3 ml/min where A is 0.1% TFA  
in H<sub>2</sub>O and B is 90% CH<sub>3</sub>CN, 0.1% TFA.

15 IMP3 was formulated in 1 mg and 250 μg amounts with  
450 μg Sn(II) and α-D-glucoheptonate at a ratio of  
1:17.5, and lyophilized. The lyophilized vials of IMP3  
(1 mg and 250 μg) were reconstituted with 617 and 578 μCi  
of NaReO<sub>4</sub> in saline. The vials were heated for 15 min at  
20 75°C. HPLC analysis under the conditions described above  
showed single peaks at RT of 7.0 min for both vials. The  
effluent was collected and counted on a γ-counter. For  
the 1 mg vial, the recovery of activity was 88% whereas  
the recovery was 77% for the 250 μg vial. Colloid  
25 analyses on an ITLC strip developed in  
H<sub>2</sub>O:EtOH:NH<sub>4</sub>OH(5:2:1) showed 1.4 and 1.2% of the activity  
at the origin for 1 mg and 250 μg vials, respectively.

<sup>188</sup>Re labeling at room temperature did not proceed as  
well as at 75°C. At room temperature, only a few percent  
30 of the activity (<5%) was incorporated into the peptide  
and the rest of the activity eluted in the void volume  
(1.2 min).

**Example 12: In vitro Receptor Binding Assays**

35 The human breast adenocarcinoma cell lines MCF-7, SK-  
BR-3, and MDA-MB-231 were used for testing radiometal  
labeled LHRH analogues. HT29 cells were used for testing

labeled VIP analogues. All cells lines were purchased from the American Type Culture Collection, Rockville, MD. Cells were grown in DMEM supplemented with 5% fetal bovine serum, 5% defined equine serum, penicillin (100 U/ml), streptomycin (100  $\mu$ g/ml), and L-glutamine (2 mM). The cells were routinely passaged after detachment with trypsin and 0.2% EDTA.

Specificity of the unlabeled LHRH analogue peptides is determined by competitive cell binding assay. Target cells are washed with fresh medium, and adjusted to  $5 \times 10^5$  cell/ml. 100 $\mu$ l of the cell suspension (100  $\mu$ l) is added per well to a 96-well microtiter plate. The cells are allowed to attach and are then treated with different concentrations of the peptides in the presence of  $^{125}$ I-LHRH (Amersham Life Science, Arlington Heights, IL, 2,000 Ci/mmol). Following a 2h incubation at room temperature with shaking, the cells are washed twice and the radioactivity associated with the cells is counted and the concentration of the peptides that cause 50% inhibition on the binding of the labeled LH-RH is compared.

To determine receptor binding constants, serial dilutions of radiolabeled LHRH are incubated with  $5 \times 10^5$  cells in a 96-well plate. All assay are performed in triplicates both with or without a high concentration of unlabeled LHRH to allow determination of specifically bound peptide. After a 2h incubation at room temperature, the cells are washed and counted. The equilibrium association constant,  $K_a$ , and the total number of receptor sites per cell are determined by Scatchard analysis.

For testing VIP analogues and their metal complexes the protocol described Virgolini et al. (Cancer Res. 54:690 (1994)) is used. Briefly,  $^{125}$ I VIP is mixed with increasing concentrations of test peptide in a solution of binding buffer, following which each solution is added to HT29 cells in a 48 well culture plate. Each concentration is tested in triplicate. The cells are




incubated at 4°C for 2h, followed by three washes with ice-cold binding buffer. The cells are then lysed with 2M NaOH for 5 min and the liquid in the well is removed with a cotton swab. The activity on the cotton swab is counted using a gamma counter.

The invention has been disclosed broadly and illustrated in reference to representative embodiments described above. Those skilled in the art will recognize that various modifications can be made to the present invention without departing from the spirit and scope thereof. Subject matter relating to radiometal-binding peptides also is described in copending U.S. application no. 08/474,555, the disclosure of which is hereby incorporated by reference in its entirety.

WHAT IS CLAIMED IS:

1. A peptide comprising a radiometal-binding moiety, wherein said binding moiety comprises the structure:



wherein R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, and a protecting group that can be removed under the conditions of peptide synthesis, provided that at least one of R<sup>1</sup>, R<sup>2</sup>, or R<sup>3</sup> is H,

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, aryl, and substituted aryl, or R<sup>4</sup> and R<sup>6</sup> together optionally form a direct bond, and R<sup>8</sup> and R<sup>9</sup> together or R<sup>7</sup> and R<sup>9</sup> together may form a cycloalkyl or substituted cycloalkyl ring, and


wherein NR<sup>10</sup> is located at the N-terminus of said peptide, or is located on an amino acid side chain of said peptide.

2. A peptide according to claim 1, wherein R<sup>1</sup> is H.
3. A peptide according to claim 1, wherein R<sup>3</sup> is H.
4. A peptide according to claim 1, wherein R<sup>4</sup> is H.
5. A peptide according to claim 1, wherein R<sup>4</sup> and R<sup>6</sup> together form a direct bond.

6. A peptide according to claim 5, wherein  $R^5$  is H.
7. A peptide according to claim 1, wherein  $NR^{10}$  is located at the N-terminus of said peptide.
8. A peptide according to claim 1, wherein  $NR^{10}$  is located on an amino acid side chain of said peptide.
9. A peptide according to claim 2, wherein  $R^2$  is lower alkyl or substituted or unsubstituted phenyl.
10. A peptide according to claim 9, wherein  $R^2$  is H.
11. A peptide according to claim 10, wherein  $R^3$  is H.
12. A peptide according to claim 11, wherein  $R^4$  and  $R^6$  together form a direct bond.
13. A peptide according to claim 12, wherein  $R^5$  is H.
14. A peptide according to claim 13, wherein  $R^7$ ,  $R^8$ , and  $R^9$  each are H.
15. A peptide according to claim 14, wherein  $R^2$  is phenyl.
16. A peptide according to claim 14, wherein  $R^2$  is methyl.
17. A peptide according to claim 1, wherein  $R^8$  and  $R^9$  are methyl.
18. A peptide according to claim 1, further comprising a bound metal atom.

19. A peptide according to claim 18, wherein said metal atom is selected from the group consisting of  $^{99m}\text{Tc}$ ,  $^{186}\text{Re}$ , and  $^{188}\text{Re}$ .

20. A method of preparing a metal-chelating composition, comprising contacting a solution of a peptide comprising a radiometal-binding moiety with stannous ions, wherein said binding moiety comprises the structure:



wherein R¹, R², and R³ independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, and a protecting group that can be removed under the conditions of peptide synthesis, provided that at least one of R¹, R², or R³ is H,

R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ and R¹⁰ independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, aryl, and substituted aryl, or R⁴ and R⁶ together optionally form a direct bond, and R⁸ and R⁹ together or R⁷ and R⁹ together may form a cycloalkyl or substituted cycloalkyl ring, and


wherein NR¹⁰ is located at the N-terminus of said peptide, or is located on an amino acid side chain of said peptide,

and then contacting said solution with a radionuclide and recovering the radiolabeled peptide.

21. The method of claim 20, wherein said radionuclide is selected from  $^{188}\text{Re}$ - or  $^{186}\text{Re}$ -perrhenate and  $^{99}\text{Tc}$ -pertechnetate.

22. A method of imaging a tumor, an infectious lesion, a myocardial infarction, a clot, atherosclerotic plaque, or a normal organ or tissue, comprising administering to a human patient a radiolabeled peptide, together with a pharmaceutically acceptable carrier, and, after a sufficient time for said radiolabeled peptide to localize and for non-target background to clear, the site or sites of accretion of said radiolabeled peptide are detected by an external imaging camera,

wherein said radiolabeled peptide is prepared by contacting a solution of a peptide with stannous ions, wherein said peptide comprises a radiometal-binding moiety comprising the structure:



wherein  $R^1$ ,  $R^2$ , and  $R^3$  independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, and a protecting group that can be removed under the conditions of peptide synthesis, provided that at least one of  $R^1$ ,  $R^2$ , or  $R^3$  is H,

$R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$  and  $R^{10}$  independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, aryl, and substituted aryl, or  $R^4$  and  $R^6$  together optionally form a direct bond, and  $R^8$  and  $R^9$  together or  $R^7$  and  $R^9$  together may form a cycloalkyl or substituted cycloalkyl ring, and

and then contacting said solution with a radionuclide and recovering the radiolabeled peptide.

(Chel)  $\gamma$ AbuNleDHF<sub>d</sub>RWK-NH<sub>2</sub>,  
(Chel)  $\gamma$ AbuHSDAVFTDNYTRLRKQMAVKKYLNSILN-NH<sub>2</sub>,  
KPRRPYTDNYTRLRK (Chel) QMAVKKYLNSILN-NH<sub>2</sub>,  
(Chel)  $\gamma$ AbuVFTDNYTRLRKQMAVKKYLNSILN-NH<sub>2</sub>,  
(Chel)  $\gamma$ AbuYTRLRKQMAVKKYLNSILN-NH<sub>2</sub>,  
HSDAVFTDNYTRLRK (Chel) QMAVKKYLNSILN-NH<sub>2</sub>,  
<GHWSYK (Chel) LRPG-NH<sub>2</sub>, <GHYSLK (Chel) WKPG-NH<sub>2</sub>,  
AcNaI<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub> (Chel) LRPA<sub>d</sub>-NH<sub>2</sub> ,  
(Chel)  $\gamma$ AbuSYSNleDHF<sub>d</sub>RWK-NH<sub>2</sub>, (Chel)  $\gamma$ AbuNleDHF<sub>d</sub>RWK-NH<sub>2</sub> ,  
(Chel) NleDHF<sub>d</sub>RWK-NH<sub>2</sub> ,  
Ac-HSDAVFTENYTKLRK (Chel) QNleAAKYLNDLKKGGT-NH<sub>2</sub>,  
(Chel)  $\gamma$ AbuHSDAVFTDNYTRLRKQMAVKKYLNSILN-NH<sub>2</sub>,  
(Chel)  $\gamma$ AbuVFTDNYTRLRKQMAVKKYLNSILN-NH<sub>2</sub>,  
(Chel)  $\gamma$ AbuNleDHF<sub>d</sub>RWK-NH<sub>2</sub><sup>c</sup>, <GHWSYK (Chel) LRPG-NH<sub>2</sub>,  
<GHYSLK (Chel) WKPG-NH<sub>2</sub>, AcNaI<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub> (Chel) LRPA<sub>d</sub>-NH<sub>2</sub>,  
<GHYSYLK (Chel) WKPG-NH<sub>2</sub>, <GHYSLK (Chel) WKPG-NH<sub>2</sub>,  
NaI<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub> (Chel) WKPG-NH<sub>2</sub>, <GHWSYK<sub>d</sub> (Chel) LRPG-NH<sub>2</sub>,  
AcNaI<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub> (Chel) LRPA<sub>d</sub>-NH<sub>2</sub>,  
AcNaI<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub> (Chel) LRPA<sub>d</sub>-NH<sub>2</sub>,  
AcNaI<sub>d</sub>Cpa<sub>d</sub>W<sub>d</sub>SRK<sub>d</sub> (Chel) LRPA<sub>d</sub>-NH<sub>2</sub>, <GHWSYK (Chel) LRPG-NH<sub>2</sub>,  
AcK (Chel) F<sub>d</sub>CFW<sub>d</sub>KTCT-OH, AcK (Chel) DF<sub>d</sub>CFW<sub>d</sub>KTCT-OH,  
AcK (Chel) F<sub>d</sub>CFW<sub>d</sub>KTCT-ol, AcK (Chel) DF<sub>d</sub>CFW<sub>d</sub>KTCT-ol,  
(Chel) DF<sub>d</sub>CFW<sub>d</sub>KTCT-OH, K (Chel) DF<sub>d</sub>CFW<sub>d</sub>KTCT-ol,  
K (Chel) KKF<sub>d</sub>CFW<sub>d</sub>KTCT-ol, K (Chel) KDF<sub>d</sub>CFW<sub>d</sub>KTCT-OH,  
K (Chel) DSF<sub>d</sub>CFW<sub>d</sub>KTCT-OH, K (Chel) DF<sub>d</sub>CFW<sub>d</sub>KTCT-OH,  
K (Chel) DF<sub>d</sub>CFW<sub>d</sub>KTCD-NH<sub>2</sub>, K (Chel) DF<sub>d</sub>CFW<sub>d</sub>KTCT-NH<sub>2</sub>,  
K (Chel) KDF<sub>d</sub>CFW<sub>d</sub>KTCT-NHNH<sub>2</sub>, AcK (Chel) F<sub>d</sub>CFW<sub>d</sub>KTCT-NHNH<sub>2</sub>,  
K (Chel) F<sub>d</sub>CFW<sub>d</sub>KTCT-ol, and F<sub>d</sub>CFW<sub>d</sub>KTCTK (Chel) -NH<sub>2</sub>,  
wherein (Chel) is said radiometal-binding moiety.



# DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

## **RADIOMETAL-BINDING PEPTIDE ANALOGUES**

the specification of which is attached hereto unless the following box is checked:

☒ was filed on July 11, 1997 as United States Application Number or PCT International Application Number 08/893,749  
and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in Title 37, Code of Federal Regulations § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

### **PRIOR FOREIGN APPLICATION(S)**

NUMBER	COUNTRY	DAY/MONTH/YEAR FILED	PRIORITY CLAIMED

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

APPLICATION NO.	FILING DATE
<u>60/021,662</u>	<u>July 12, 1996</u>

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS: PATENTED, PENDING, ABANDONED

I hereby appoint as my attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Stephen A. Bent, Reg. No. 29,768; David A. Blumenthal, Reg. No. 26,257; William T. Ellis, Reg. No. 26,874; John J. Feldhaus, Reg. No. 28,822; Patricia D. Granados, Reg. No. 33,683; John P. Isacson, Reg. No. 33,715; Donald D. Jeffery, Reg. No. 19,980; Eugene M. Lee, Reg. No. 32,039; Peter G. Mack, Reg. No. 26,001; Brian J. McNamara, Reg. No. 32,789; Sybil Meloy, Reg. No. 22,749; George E. Quillin, Reg. No. 32,792; Colin G. Sandercock, Reg. No. 31,298; Bernhard D. Saxe, Reg. No. 28,665; Charles F. Schill, Reg. No. 27,590; Richard L. Schwaab, Reg. No. 25,479; Arthur Schwartz, Reg. No. 22,115; Harold C. Wegner, Reg. No. 25,258.

Address all correspondence to FOLEY & LARDNER, 3000 K Street, N.W., Suite 500, Washington, DC 20007-5109. Address telephone communications to Bernhard D. Saxe at (202) 672-5300.



SECRET NO. 01075570007

I hereby declare that all statements made herein or my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First or Sole Inventor <i>William J. McBRIDE</i>	Signature of First or Sole Inventor <i>William J. McBride</i>	Date <i>9-9-97</i>
Residence Address <i>Summit, New Jersey 07901</i>	Country of Citizenship <i>U.S.A.</i>	
Post Office Address <i>767 Springfield Avenue #6, Summit, New Jersey 07901</i>		

Full Name of First or Sole Inventor <i>Gary L. GRIFFITHS</i>	Signature of First or Sole Inventor <i>G. L. Griffiths</i>	Date <i>9/11/97</i>
Residence Address <i>Morristown, New Jersey 07960</i>	Country of Citizenship <i>Great Britain</i>	
Post Office Address <i>36 Edgehill Avenue, Morristown, New Jersey 07960</i>		